INSECTICIDE TARGETS AND METHODS OF USE

Abstract: Nucleic acids isolated from <i>Drosophila melanogaster</i> that are lethal when knocked out in <i>Drosophila</i>, and proteins encoded thereby, are described. The nucleic acids and proteins can be used to genetically modify metazoan invertebrate organisms, such as insects and worms, or cultured cells, resulting in expression or mis-expression of the encoded proteins. The genetically modified organisms or cells can be used in screening assays to identify candidate compounds which are potential pesticidal agents or therapeutics that interact with subject proteins. They can also be used in methods for studying activity of subject proteins, and identifying other genes that modulate the function of, or interact with, the subject genes.

Description: INSECTICIDE TARGETS AND METHODS OF USE BACKGROUND OF THE INVENTION Hehcases are crucial to the utilization of DNA by cell metabolism Double stranded DNA must be unwound in order to participate in such nuclear dynamics as replication, transcription and repair This unwinding is controlled in a specific manner by a number of DNA hehcases (more than 15 have been identified in yeast, bacteria and mammalian cells) In bacteria, RuvB-hke hehcases are involved in complexes at Holhday junctions which include RuvA, RuvB and RuvC RuvBs are dodecamenc assemblies of two hexameπc nngs with ATPase activity when bound to DNA with Magnesium and ATP TIP49b appears to be the mammalian homolog of the bacterial RuvB proteins The RuvA-RuvB complex m the presence of ATP renatures cruciform structure in supercoiled DNA with pahndromic sequence, indicating that it may promote strand exchange reactions m homologous recombination RuvB mediates the Holhday junction migration by localized denaturation and re-annealmg RuvB catalyzes homologous recombination and double-strand break repair When double- strand breaks occur in DNA (by X-ray radiation or nuclease activity), the DNA ends are processed by RecBCD and introduced into homologous sequences in a heterologous duplex by RecA (Kowalczykowski et al , Microbiol Rev (1994) 58 401-465 ) This mechanism forms a homologous recombination-directed intermediate having a four-way junction, namely the Holhday structure In the late-stage of homologous recombination, RuvB binds to the Holhday structure, and a branch point migrates dependent on the DNA hehcase activity of RuvB Then RuvC,a Holhday structure-specific endonuclease, resolves the junction TIP49a and TIP49b are both mammalian homologs of bacterial RuvB, and are found in the same -700 kDa complex in the cell, suggesting strong evolutionary conservation of these genes TIP49a and TIP49b share similar enzymatic properties, however, the polarity of TIP49b's hehcase activity (5' to 3', same as RuvB) is reversed relative to TIP49a Both TIP49a and TIP49b have been shown to be independently essential for cell growth, suggesting that their activities are not complementary In E coli, RuvA, RuvB and RuvC are all found sequentially on the chromosome, this does not appear to be true m eukaryotic cells Phosphohpid transfer proteins are found m organisms from yeast to man and catalyze the transfer of phosphohpids between membranes Phophatidyhnositol transfer proteins (PITPs), possess dual capability, transporting both phosphatidyhnositol and phosphatidylchohne PITP also plays essential roles in the phosphohpase C- (PLC) mediated inositol hpid signaling of mammalian cells and m the formation of vesicles (Thomas et al , Cell, (1993) 74 919-928). and is necessary for regulated exocytosis (Helkamp, Subcell Biochem (1990) 16 129-174, Bankaitis, et al , Nature (1990) 347 561- 562) The protein sequences of PITPs are highly conserved among species Mammalian species have multiple isoforms Alpha- and beta- isoforms of PITP share less sequence identity within a given species than each isoform shares across species, suggestmg that each isoform have distinct and conserved roles The beta isoform is capable of transferring sphingomyehn in addition to phohatidylmositol (PI) and phosphatidylchohne (PC) The alpha isoform neither binds nor transports sphingomyehn, the same is true of yeast Sec 14 and the fruitfly Drosophila melanogaster (hereinafter Drosophila) protein rdgB (Westerman et al J Biol Chem , (1995) 270 14263-14266) The ability to bind and transfer PI/PC between membrane compartments defines this family of protems A related protem, rdgB, from Drosophila shares significant sequence homology m an N- termmal 281 am o acid domain, however, it is an integral membrane protein (1,054 am o acids) and therefore cannot carry out the transfer of hpids between membranes Expression of that protein without the membrane anchor enables it to translocate hpids amongst membranes The rdgB protein plays a role in the retinal degradation cascade involved in signal transduction from the retina (Vihtehc et al , J Cell Biol (1993) 122 1013-1022) In yeast, Secl4 has been identified as a protein with homologous function (transport of PI/PC amongst membranes), but shows no significant sequence conservation with the mammalian PITPs At the level of the intact organism, disruption of the expression level of PITP alpha isoform (hereinafter PITP-α) leads to neurodegeneration The "vibrator" mouse has a neurodegenerative disorder manifested by tremors that develop into an ultimately fatal, ascending motor paralysis It has been determined that the mutant "vibrator" gene (vb) results in decreased expression of PITP-α and is the primary cause of neurodegeneration in these animals (Hamilton, Neuron, (1997) 18 711-722) Homozygous mutant mice die from apnea at post-natal day 30-160 Histological analyses indicate that the vb defect elicits a highly restricted degeneration that is limited to neurons of the spinal cord, brain stem and dorsal root ganglia Thus, specific neuronal cells are particularly sensitive to PITP-α deficiency How PITP-α prevents neurodegeneration remains unknown Deletion mutants of PITP-α have been made which impact upon the functional properties of the protein It has been shown that the extreme C-terminus is crucial to a structural recognition event m the PLC cascade, and that hpid binding is in some manner affected by the loss of residues between 2 1-261 either directly or through some loss of structural integrity imperative to the hpid bmdmg site (Prosser et al , Biochem J , (1997) 324 19-23) Sphmgohpids and their metabolic derivatives elicit a wide variety of eukaryotic cellular responses Although the stimuli and biological end points differ in each cell type, the role of sphingohpid by-products as second messengers in specific, growth regulatory signal transduction pathways appears to be a universal theme among eukaryotic cells (Hannun, J. Biol. Chem. (1994) 269:3125-3128). Sphingosine and sphingosine 1 -phosphate (S-l-P) are both catabolites of sphingolipid breakdown, which have been shown to modulate DNA synthesis and cellular proliferation in mammalian cells (Olivera and Spiegel Nature (1993) 365:557-559). Evidence suggests that S-l-P is largely responsible for these effects. In addition, S-l-P has recently been shown to inhibit the growth, motility, and invasiveness of tumor cells (Sadahira et al, Proc. Natl. Acad. Sci. U. S. A. (1992) 89:9686-9690; Spiegel et al, Breast Cancer Res. Treat. (1994) 31 :337-348). Free sphingosine and S-l-P are maintained at very low levels in mammalian cells (Merrill et al, Anal. Biochem. (1988) 171:373-381). This is consistent with the notion that potent second messengers are tightly regulated in the absence of a particular stimulus. The mechanism(s) by which the intracellular levels of sphingosine and S- 1 -P are regulated have not been established. Such control may occur at the synthetic stage, via regulation of the activities of ceramidases and sphingosine kinase (Buehrer and Bell, Adv. Lipid Res. (1993) 26:59-67). Alternatively, control may occur at the catabolic stage, through regulation of the activity of sphingosine phosphate lyase (SPL) (Veldhoven and Mannaerts, Adv. Lipid Res. (1993) 26:69-98). Sphingolipids exist in yeast where they provide vital, yet unknown functions (Wells, and Lester, J. Biol. Chem. (1983) 258, 10200- 10203). S-l-P has also been shown to be associated with the enhanced expression of the Bax protein, which is involved in apoptosis (Hung and Chuang, Biochem. Biophys. Res. Comm. (1996) 229: 11-15). S-l-P blocks cell death induced by ceramide and tumor necrosis factor-alpha (Cuvillier et al, Nature (1996) 81:800-803). Pesticide development has traditionally focused on the chemical and physical properties of the pesticide itself, a relatively time-consuming and expensive process. As a consequence, efforts have been concentrated on the modification of pre-existing, well-validated compounds, rather than on the development of new pesticides. There is a need in the art for new pesticidal compounds that are safer, more selective, and more efficient than currently available pesticides. The present invention addresses this need by providing novel pesticide targets from invertebrates such as the fruit fly Drosophila melanogaster, and by providing methods of identifying compounds that bind to and modulate the activity of such targets. SUMMARY OF THE INVENTION It is an object of the invention to provide insect nucleic acids and proteins that are targets for pesticides. The insect nucleic acid molecules provided herein are useful for producing insect proteins encoded thereby. The insect proteins are useful in assays to identify compounds that modulate a biological activity of the proteins, which assays identify compounds that may have utility as pesticides. It is an object of the present invention to provide invertebrate homologs of a Hehcase, hereinafter referred to as dmHelicase, that can be used in genetic screening methods to characterize pathways that dmHelicase may be involved in as well as other interacting genetic pathways. It is also an object of the invention to provide methods for screening compounds that interact with dmHelicase such as those that may have utility as therapeutics or pesticides. It is a further object of the present invention to provide invertebrate homologs of a PITP, hereinafter referred to as dmPITP, that can be used in genetic screening methods to characterize pathways that dmPITP may be involved in as well as other interacting genetic pathways. It is also an object of the invention to provide methods for screening compounds that interact with dmPITP such as those that may have utility as therapeutics or pesticides. It is a further object of the present invention to provide invertebrate homologs of a SPL gene, hereinafter referred to as dmSPLl, that can be used in genetic screening methods to characterize pathways that dmSPLl may be involved in as well as other interacting genetic pathways. It is also an object of the invention to provide methods for screening compounds that interact with dmSPLl such as those that may have utility as therapeutics or pesticides. These and other objects are provided by the present invention, which concerns the identification and characterization of novel pesticidal targets in Drosophila melanogaster that are lethal when knocked out in Drosophila. Isolated nucleic acid molecules are provided that comprise nucleic acid sequences encoding target proteins as well as novel fragments and derivatives thereof. Methods of using the isolated nucleic acid molecules and fragments of the invention as biopesticides are described, such as use of RNA interference methods that block a biological activity of the target protein. Vectors and host cells comprising the subject nucleic acid molecules are also described, as well as metazoan invertebrate organisms (e.g. insects, coelomates and pseudocoelomates) that are genetically modified to express or mis-express a subject protein. An important utility of the novel target nucleic acids and proteins is that they can be used in screening assays to identify candidate compounds which are potential pesticidal agents or therapeutics that interact with a target protein. Such assays typically comprise contacting a subject protein or fragment with one or more candidate molecules, and detecting any interaction between the candidate compound and the subject protein. The assays may comprise adding the candidate molecules to cultures of cells genetically engineered to express subject proteins, or alternatively, administering the candidate compound to a metazoan invertebrate organism genetically engineered to express a subject protein. The genetically engineered metazoan invertebrate animals of the invention can also be used in methods for studying a biological activity of a subject protein. These methods typically involve detecting the phenotype caused by the expression or mis-expression of the subject protein. The methods may additionally compose observing a second animal that has the same genetic modification as the first animal and, additionally has a mutation in a gene of mterest Any difference between the phenotypes of the two animals identifies the gene of interest as capable of modifying the function of the gene encodmg the subject protein DETAILED DESCRIPTION OF THE INVENTION The use of invertebrate model orgamsm genetics and related technologies can greatly facilitate the elucidation of biological pathways (Scangos, Nat Biotechnol (1997) 15 1220-1221, Margohs and Duyk, supra) Of particular use is the insect model organism, Drosophila melanogaster (hereinafter referred to generally as "Drosophila") An extensive search for Hehcase nucleic acids and their encoded proteins in Drosophila was conducted in an attempt to identify new and useful tools for probing the function and regulation of the Hehcase genes, and for use as targets in pesticide and drug discovery Novel insect nucleic acid molecules, and proteins encoded thereby, are provided herein Novel nucleic acids and their encoded proteins are identified herein The Drosophila target nucleic acids and proteins presented here were identified via mutation to lethality by P-element transposon insertion, discussed in more detail below The P-element lethality, along with the DNA processing functions, identifies the subject Drosophila proteins as previously unrecognized msecticidal drug targets for antagonist drugs The newly identified nucleic acids can be used for the generation of mutant phenotypes in animal models or in living cells that can be used to study regulation of proteins encoded by the subject nucleic acid molecules, and the use of subject proteins as pesticide or drug targets Due to the ability to rapidly carry out large-scale, systematic genetic screens, the use of invertebrate model organisms such as Drosophila has great utility for analyzing the expression and mis-expression of a subject protein Thus, the provides a superior approach for identifying other components involved in the synthesis, activity, and regulation of the subject proteins Systematic genetic analysis of the subject protems using invertebrate model organisms can lead to the identification and validation of pesticide targets directed to components of biochemical pathways involving the subject proteins Model organisms or cultured cells that have been genetically engineered to express the subject proteins can be used to screen candidate compounds for their ability to modulate subject protein expression or activity, and thus are useful in the identification of new drug targets, therapeutic agents, diagnostics and prognostics useful m the treatment of disorders associated with DNA processing Additionally, these invertebrate model organisms can be used for the identification and screening of pesticide targets directed to components of a pathway involving a subject protein The details of the conditions used for the identification and/or isolation of novel subject nucleic acid and protein are described in the Examples section below Various non-limiting embodiments of the mvention, applications and uses of these novel gene and protem are discussed in the following sections The enure contents of all references, including patent applications, cited herein are incorporated by reference in their entireties for all purposes Additionally, the citation of a reference in the precedmg background section is not an admission of pπor art against the claims appended hereto For the purposes of the present application, singular forms "a", "and", and "the" include plural referents unless the context clearly indicates otherwise Thus, for example, reference to "an invertebrate receptor" includes large numbers of receptors, reference to "an agent" includes large numbers of agents and mixtures thereof, reference to "the method" includes one or more methods or steps of the type described herein Definitions As used herein the term "isolated" is meant to describe a polynucleotide, a polypeptide, an antibody, or a host cell that is m an environment different from that in which the polynucleotide, the polypeptide, the antibody, or the host cell naturally occurs As used herein, the term "substantially purified" refers to a compound (e g , either a polynucleotide or a polypeptide or an antibody) that is removed from its natural environment and is at least 60% free, preferably 75% free, and most preferably 90% free from other components with which it is naturally associated A "host cell", as used herein, denotes microorganisms or eukaryotic cells or cell lines cultured as unicellular entities which can be, or have been, used as recipients for recombinant vectors or other transfer polynucleotides, and include the progeny of the original cell which has been transfected It is understood that the progeny of a single cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation By "transformation" is meant a permanent or transient genetic change induced m a cell following incorporation of new DNA (I e , DNA exogenous to the cell) Genetic change can be accomplished either by incorporation of the new DNA into the genome of the host cell, or by transient or stable maintenance of the new DNA as an episomal element Where the cell is a eukaryotic cell, a permanent genetic change is generally achieved by introduction of the DNA into the genome of the cell Isolated nucleic acids of the invention The present invention provides isolated nucleic acid molecules that comprise nucleotide sequences encodmg insect proteins that are potential pesticide targets The isolated nucleic acid molecules have a variety of uses, e g , as hybridization probes, e g , to identify nucleic acid molecules that share nucleotide sequence identity, in expression vectors to produce the polypeptides encoded by the nucleic acid molecules, and to modify a host cell or animal for use in assays described herembelow Thus, the term "isolated nucleic acid sequence", as used herein, includes the reverse complement, RNA equivalent, DNA or RNA single- or double-stranded sequences, and DNA/RNA hybπds of the sequence being descnbed, unless otherwise indicated The terms "polynucleotide" and "nucleic acid", used interchangeably herein, refer to a polymeric forms of nucleotides of any length, either πbonucleotides or deoxynucleotides Thus, this tern includes, but is not limited to, single-, double-, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA- RNA hybπds, or a polymer comprising punne and pynmidme bases or other natural, chemically or biochemically modified, non-natural, or denvatized nucleotide bases The backbone of the polynucleotide can compπse sugars and phosphate groups (as may typically be found m RNA or DNA), or modified or substituted sugar or phosphate groups Alternatively, the backbone of the polynucleotide can compπse a polymer of synthetic subunits such as phosphoramidites and thus can be an ohgodeoxynucleoside phosphoramidate or a mixed phosphoramidate-phosphodiester ohgomer Peyrottes et al (\99G) Nucl Acids Res 24 1841-1848, Chaturvedi et al (1996) Nutl Acids Res 24 2318-2323 A polynucleotide may compπse modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracyl, other sugars, and linking groups such as fluoroπbose and thioate, and nucleotide branches The sequence of nucleotides may be interrupted by non-nucleotide components A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component Other types of modifications included in this definition are caps, substitution of one or more of the naturally occurπng nucleotides with an analog, and introduction of means for attaching the polynucleotide to proteins, metal ions, labeling components, other polynucleotides, or a solid support For hybπdization probes, it may be desirable to use nucleic acid analogs, in order to improve the stability and and bindmg affinity A number of modifications have been described that alter the chemistry of the phosphodiester backbone, sugars or heterocychc bases Among useful changes in the backbone chemistry are phosphorothioates, phosphorodithioates, where both of the non-bridging oxygens are substituted with sulfur, phosphoroamidites, alkyl phosphotπesters and boranophosphates Achrral phosphate deπvatives include 3'-0'-5'-S- phosphorothioate, 3'-S-5'-0-phosphorothιoate, 3'-CH2-5'-0-phosphonate and 3'-NH-5'-0- phosphoroamidate Peptide nucleic acids replace the entire phosphodiester backbone with a peptide linkage Sugar modifications are also used to enhance stability and affinity The a-anomer of deoxyπbose may be used, where the base is inverted with respect to the natural b-anomer The 2'-OH of the πbose sugar may be altered to form 2'-0-methyl or 2'-0-allyl sugars, which provides resistance to degradation without compnsing ai finity Modification of the heterocychc bases must mamtam proper base pairing Some useful substitutions include deoxyuπdme for deoxythymidine, 5-methyl-2'- deoxycytidine and 5-bromo-2'-deoxycytιdme for deoxycytidme 5- propynyl-2'-deoxyuπdme and 5- propynyl-2'-deoxycytιdme have been shown to increase affinity and biological activity when substituted for deoxythymidine and deoxycytidme, respectively Deπvative nucleic acid sequences of the subject nucleic acid molecules include sequences that hybπdize to the nucleic acid sequence of any one of SEQ ID NOS 1 , 3, or 5 under stringency conditions such that the hybπdizmg derivative nucleic acid is related to the subject nucleic acid by a certain degree of sequence identity A nucleic acid molecule is "hybπdizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule Stringency of hybridization refers to conditions under which nucleic acids are hybπdizable The degree of stringency can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybπdization and washing As used herein, the term "stringent hybridization conditions" are those normally used by one of skill in the art to establish at least a 90% sequence identity between complementary pieces of DNA or DNA and RNA "Moderately stπngent hybπdization conditions" are used to find derivatives having at least 70% sequence identity Finally, "low-stringency hybπdization conditions" are used to isolate derivative nucleic acid molecules that share at least about 50% sequence identity with the subject nucleic acid sequence The ultimate hybπdization stπngency reflects both the actual hybridization conditions as well as the washing conditions following the hybridization, and it is well known in the art how to vary the conditions to obtain the desired result Conditions routinely used are set out m readily available procedure texts (e g , Current Protocols in Molecular Biology, Vol 1, Chap 2 10. John Wiley & Sons, Publishers (1994), Sambrook et al , Molecular Cloning, Cold Spring Harbor (1989)) A preferred deπvative nucleic acid is capable of hybridizing to SEQ ID NO 1 under stringent hybridization conditions that compπse prehybπdization of filters containing nucleic acid for 8 hours to overnight at 65° C in a solution comprising 6X single strength citrate (SSC) (IX SSC is 0 15 M NaCl, 0 015 M Na citrate, pH 7 0), 5X Denhardt's solution, 0 05% sodium pyrophosphate and 100 μg/ml herring sperm DNA. hybπdization for 18-20 hours at 65° C in a solution containing 6X SSC, IX Denhardt's solution, 100 μg/ml yeast tRNA and 0 05% sodium pyrophosphate, and washing of filters at 65° C for 1 h in a solution containing 0 2X SSC and 0 1% SDS (sodium dodecyl sulfate) Fragments of the subject nucleic acid molecules can be used for a vaπety of purposes Interfering RNA (RNAi) fragments, particularly double-stranded (ds) RNAi, can be used to generate loss-of-function phenotypes, or to formulate biopesticides (discussed further below) Fragments of the subject nucleic acid molecules are also useful as nucleic acid hybπdization probes and replication/amplification primers Certain "antisense" fragments, 1 e that are reverse complements of portions of the coding sequence of the subject nucleic acid sequences have utility in inhibiting the function of protems encoded by the subject nucleic acid molecules The fragments are of length sufficient to specifically hybπdize with the corresponding subject nucleic acid molecule The fragments generally consist of or compπse at least 12, preferably at least 24, more preferably at least 36, and more preferably at least 96 contiguous nucleotides of a subject nucleic acid molecule When the fragments are flanked by other nucleic acid sequences, the total length of the combined nucleic acid sequence is less than 15 kb, preferably less than 10 kb or less than 5kb, more preferably less than 2 kb, and in some cases, preferably less than 500 bases The subject nucleic acid sequences and fragments thereof may be joined to other components such as labels, peptides, agents that facilitate transport across cell membranes, hybridization-triggered cleavage agents or intercalating agents The subject nucleic acid sequences and fragments thereof may also be joined to other nucleic acid sequences (i e they may comprise part of larger sequences) and are of synthetic/non-natural sequences and/or are isolated and/or are purified, I e unaccompanied by at least some of the material with which it is associated in its natural state Preferably, the isolated nucleic acids constitute at least about 0 5%, and more preferably at least about 5% by weight of the total nucleic acid present in a given fraction, and are preferably recombinant, meaning that they comprise a non-natural sequence or a natural sequence joined to nucleotιde(s) other than that which it is joined to on a natural chromosome Derivative nucleic acid sequences that have at least about 70% sequence identity with one of SEQ ID NOS l, 3, or 5 are capable of hybridizing to one of SEQ ID NOS 1, 3, or 5 under moderately stringent conditions that comprise pretreatment of filters containing nucleic acid for 6 hours at 40° C m a solution containing 35% formamide, 5X SSC, 50 mM Tπs-HCl (pH 7 5), 5 mM EDTA, 0 1% PVP, 0 1% Ficoll, 1% BSA, and 500 μg/ml denatured salmon sperm DNA, hybridization for 18-20 h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tπs-HCl (pH 7 5), 5 mM EDTA, 0 02% PVP, 0 02% Ficoll, 0 2% BSA, 100 μg/ml salmon sperm DNA, and 10% (wt/vol) dextran sulfate, followed by washing twice for 1 hour at 55° C in a solution containing 2X SSC and 0 1% SDS Other preferred derivative nucleic acid sequences are capable of hybridizing to one of SEQ ID NOS 1, 3, or 5 under low stringency conditions that comprise incubation for 8 hours to overnight at 37° C in a solution comprising 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7 6), 5X Denhardt's solution, 10% dextran sulfate, and 20 μg/ml denatured sheared salmon sperm DNA, hybπdization in the same buffer for 18 to 20 hours, and washing of filters in 1 x SSC at about 37° C for 1 hour As used herem, "percent (%) nucleic acid sequence identity" with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of nucleotides m the candidate deπvative nucleic acid sequence identical with the nucleotides m the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2 Oal 9 (Altschul et al , J Mol Biol ( 1997) 215 403-410, http //blast wustl edu/blast/README html, hereinafter referred to generally as "BLAST") with all the search parameters set to default values The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched A percent (%) nucleic acid sequence identity value is determined by the number of matching identical nucleotides divided by the sequence length for which the percent identity is being reported Another type of derivative of the subject nucleic acid sequences includes corresponding humanized sequences A humanized nucleic acid sequence is one in which one or more codons has been substituted with a codon that is more commonly used in human genes Preferably, a sufficient number of codons have been substituted such that a higher level expression is achieved in mammalian cells than what would otherwise be achieved without the substitutions Tables are available in the art that show, for each amino acid, the calculated codon frequency in humans genes for 1000 codons (Wada et al , Nucleic Acids Research (1990) 18(Suppl ) 2367-2411) Similarly, other nucleic acid derivatives can be generated with codon usage optimized for expression in other organisms, such as yeasts, bacteria, and plants, where it is desired to engineer the expression of receptor proteins by using specific codons chosen according to the prefeπed codons used m highly expressed genes m each organism A detailed discussion ofthe humamzation of nucleic acid sequences is provided in U S Pat No 5,874,304 to Zolotukhin et al A derivative invertebrate target nucleic acid sequence, or fragment thereof, may comprise 100% sequence identity with any one of SEQ ID NOS 1, 3, or 5 but be a derivative thereof in the sense that it has one or more modifications at the base or sugar moiety, or phosphate backbone Examples of modifications are well known in the art (Bailey, Ullmann's Encyclopedia of Industrial Chemistry (1998), 6th ed Wiley and Sons) Such derivatives may be used to provide modified stability or any other desired property Exemplary target nucleic acid molecules of the mvention are described in detail below dmHelicase Nucleic Acids In some embodiments, the invention provides nucleic acid sequences of Hehcases, and more particularly Helicase nucleic acid sequences of Drosophila, and methods of using these sequences. As described in the Examples below, a nucleic acid sequence (SEQ ID NO: 1) was isolated from Drosophila that encodes a Helicase homolog, hereinafter referred to as dmHelicase. In addition to the fragments and derivatives of SEQ ID NO: 1 as described in detail below, the invention includes the reverse complements thereof. Also, the subject nucleic acid sequences, derivatives and fragments thereof may be RNA molecules comprising the nucleotide sequence of SEQ ID NO: 1 (or derivative or fragment thereof) wherein the base U (uracil) is substituted for the base T (thymine). The DNA and RNA sequences of the invention can be single- or double-stranded. Thus, the term "isolated nucleic acid sequence", as used herein, includes the reverse complement, RNA equivalent, DNA or RNA single- or double-stranded sequences, and DNA/RNA hybrids of the sequence being described, unless otherwise indicated. In some embodiments, a dmHelicase nucleic acid molecule comprises at least about 20, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000, at least about 1100, at least about 1200, at least about 1300, at least about 1400, at least about 1500, at least about 1600, at least about 1700, or at least about 1750 contiguous nucleotides of the sequence set forth in SEQ ID NO: 1, up to the entire sequence set forth in SEQ ID NO: 1. In other embodiments, a dmHelicase nucleic acid molecule of the invention comprises a nucleotide sequence that encodes a polypeptide comprising at least about 6, at least about 10, at least about 20, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400, at least about 450, or at least about 475 contiguous amino acids of the sequence set forth in SEQ ID NO:2, up to the entire amino acid sequence as set forth in SEQ ID NO:2. A preferred fragment of SEQ ID NO:l comprises nucleotides 380-401, which encode an ATP/GTP binding site motif A. Derivative dmHelicase nucleic acid sequences usually have at least 80% sequence identity, preferably at least 85% sequence identity, more preferably at least 90% sequence identity, still more preferably at least 95% sequence identity, and most preferably at least 98% sequence identity with SEQ ID NO:l. In one preferred embodiment, the derivative nucleic acid encodes a polypeptide comprising a dmHelicase amino acid sequence of SEQ ID NO:2, or a fragment or derivative thereof as described further below under the subheading "dmHelicase proteins". More specific embodimen s of preferred dmHelicase protein fragments and derivatives are discussed further below in connect on with specific dmHelicase proteins. dmPITP nucleic acid molecules In some embodiments, the invention provides nucleic acid sequences of PITPs, and more particularly PITP nucleic acid sequences of Drosophila, and methods of using these sequences. As described in the Examples below, a nucleic acid sequence (SEQ ID NO:3) was isolated from Drosophila that encodes a PITP homolog, hereinafter referred to as dmPITP. In addition to the fragments and derivatives of SEQ ID NO:3 as described in detail below, the invention includes the reverse complements thereof. In some embodiments, a dmPITP nucleic acid molecule of the invention comprises at least about 20, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000, or at least about 1050 contiguous nucleotides of the sequence set forth in SEQ ID NO:3, up to the entire sequence set forth in SEQ ID NO:3. In other embodiments, a dmPITP nucleic acid molecule of the invention comprises a nucleotide sequence that encodes a polypeptide comprising at least about 6, at least about 10, at least about 20, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 250, or at least about 270 contiguous amino acids of the sequence set forth in SEQ ID NO:4, up to the entire amino acid sequence as set forth in SEQ ID NO:4. Derivative dmPITP nucleic acid sequences usually have at least 70% sequence identity, preferably at least 80% sequence identity, more preferably at least 85% sequence identity, still more preferably at least 90% sequence identity, and most preferably at least 95% sequence identity with SEQ ID NO: 1, or domain-encoding regions thereof. In one prefeπed embodiment, the derivative nucleic acid encodes a polypeptide comprising a dmPITP amino acid sequence of SEQ ID NO:2, or a fragment or derivative thereof as described further below under the subheading "dmPITP proteins". More specific embodiments of preferred dmPITP protein fragments and derivatives are discussed further below in connection with specific dmPITP proteins. dmSPL nucleic acid molecules In some embodiments, the invention provides nucleic acid sequences of SPLs, and more particularly SPL nucleic acid sequences oi Drosophila, and methods of using these sequences. As described in the Examples below, a nucleic acid sequence (SEQ ID NO:5) was isolated from Drosophila that encodes a SPL homolog, heremafter refeπed to dmSPLl In addition to the fragments and deπvatives of SEQ ID NO 5 as descπbed m detail below, the invention mcludes the reverse complements thereof In some embodiments, a dmSPL nucleic acid molecule compπses at least about 20, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000, at least about 1100, at least about 1200, at least about 1300, at least about 1400, at least about 1500, at least about 1600. at least about 1700, at least about 1800, at least about 1900, at least about 2000, or at least about 2050 contiguous nucleotides of the sequence set forth m SEQ ID NO 5, up to the entire sequence set forth in SEQ ID NO 5 In other embodiments, a dmSPL nucleic acid molecule of the invention comprises a nucleotide sequence that encodes a polypeptide compπsing at least about 6, at least about 10, at least about 20, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400, at least about 450. at least about 500, or at least about 545 contiguous amino acids of the sequence set forth in SEQ ID NO 6 Additional preferred fragments of SEQ ID NO 5 encode extracellular or intracellular domains, which are located at approximately nucleotides 110-1008, and 1058-1744 Deπvative dmSPLl nucleic acid sequences usually have at least 70% sequence identity, preferably at least 80% sequence identity, more preferably at least 85% sequence identity, still more preferably at least 90% sequence identity, and most preferably at least 95% sequence identity with SEQ ID NO 5, or domain-encoding regions thereof More specific embodiments of prefeπed dmSPLl protein fragments and derivatives are discussed further below in connection with specific dmSPLl proteins Isolation, Production, And Expression of Subject Nucleic Acids Nucleic acid encoding the ammo acid sequence of any of SEQ ID NOS 2, 4, or 6, or fragment or deπvative thereof, may be obtained from an appropriate cDNA library prepared from any eukaryotic species that encodes a subject protein such as vertebrates, preferably mammalian (e g primate, porcme, bovine, felme, equme, and canine species, etc ) and invertebrates, such as arthropods, particularly insects species (preferably Drosophila), acarids. Crustacea, molluscs, nematodes, and other worms An expression library can be constructed using known methods For example, mRNA can be isolated to make cDNA which is hgated into a suitable expression vector for expression in a host cell into which it is introduced Various screening assays can then be used to select for the gene or gene product (e g oligonucleotides of at least about 20 to 80 bases designed to identify the gene of interest, or labeled antibodies that specifically bind to the gene product). The gene and/or gene product can then be recovered from the host cell using known techniques. Polymerase chain reaction (PCR) can also be used to isolate nucleic acids of the subject proteins, where oligonucleotide primers representing fragmentary sequences of interest amplify RNA or DNA sequences from a source such as a genomic or cDNA library (as described by Sambrook et al, supra). Additionally, degenerate primers for amplifying homologs from any species of interest may be used. Once a PCR product of appropriate size and sequence is obtained, it may be cloned and sequenced by standard techniques, and utilized as a probe to isolate a complete cDNA or genomic clone. Fragmentary sequences of the subject nucleic acids and derivatives may be synthesized by known methods. For example, oligonucleotides may be synthesized using an automated DNA synthesizer available from commercial suppliers (e.g. Biosearch, Novato, CA; Perkin-Elmer Applied Biosystems, Foster City, CA). Antisense RNA sequences can be produced intracellularly by transcription from an exogenous sequence, e.g. from vectors that contain antisense nucleic acid sequences. Newly generated sequences may be identified and isolated using standard methods. A subject isolated nucleic acid sequence can be inserted into any appropriate cloning vector, for example bacteriophages such as lambda derivatives, or plasmids such as pBR322, pUC plasmid derivatives and the Bluescript vector (Stratagene, San Diego, CA). Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., or into a transgenic animal such as a fly. The transformed cells can be cultured to generate large quantities of a subject nucleic acid. Suitable methods for isolating and producing the subject nucleic acid sequences are well-known in the art (Sambrook et al, supra; DNA Cloning: A Practical Approach, Vol. 1, 2, 3, 4, (1995) Glover, ed., MRL Press, Ltd., Oxford, U.K.). The nucleotide sequence encoding a subject protein or fragment or derivative thereof, can be inserted into any appropriate expression vector for the transcription and translation of the inserted protein-coding sequence. Alternatively, the necessary transcriptional and translational signals can be supplied by the native subject gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence such as mammalian cell systems infected with virus (e.g. vaccinia virus, adenovirus, etc); insect cell systems infected with virus (e.g. baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. Expression of a subject protein may be controlled by a suitable promoter/enhancer element. In addition, a host cell strain may be selected which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. To detect expression of the subject gene product, the expression vector can compπse a promoter operably linked to a subject gene nucleic acid, one or more oπgms of replication, and, one or more selectable markers (e g thymidme kinase activity, resistance to antibiotics, etc ) Alternatively, recombinant expression vectors can be identified by assaying for the expression of a subject gene product based on the physical or functional properties of a subject protein m in vitro assay systems (e g immunoassays) The subject proteins, fragments, or deπvatives may be optionally expressed as a fusion, or chimeric protein product (1 e it is joined via a peptide bond to a heterologous protein sequence of a different protein) A chimeric product can be made by hgating the appropriate nucleic acid sequences encoding the desired ammo acid sequences to each other in the proper coding frame using standard methods and expressing the chimeric product A chimeric product may also be made by protein synthetic techniques, e g by use of a peptide synthesizer Once a recombinant that expresses a subject gene sequence is identified, the gene product can be isolated and purified using standard methods (e g ion exchange, affinity, and gel exclusion chromatography, centπfugation, differential solubility, electrophoresis) The amino acid sequence of the protein can be deduced from the nucleotide sequence of the chimeric gene contained in the recombinant and can thus be synthesized by standard chemical methods (Hunkapiller et al , Nature (1984) 310 105- 111) Alternatively, native subject proteins can be purified from natural sources, by standard methods (e g lmmunoaffinity purification) Target Proteins of the Invention Purified target proteins of the invention comprise or consist of an ammo acid sequence of any of SEQ ID NOS 2, 4, or 6. or fragments or derivatives thereof Compositions comprising any of these proteins may consist essentially of a subject protein, fragments, or derivatives, or may comprise additional components (e g pharmaceutically acceptable caπiers or excipients, culture media, caπiers used m pesticide formulations, etc ) Deπvatives of the subject protems typically share a certain degree of sequence identity or sequence similarity with any of SEQ ID NOS 2, 4, or 6. or a fragment thereof As used herein, "percent (%) amino acid sequence identity" with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of amino acids in the candidate derivative amino acid sequence identical with the ammo acid in the subject sequence (or specified portion thereof), after aligning the sequences and introducmg gaps, if necessary to achieve the maximum percent sequence identity, as generated by BLAST (Altschul et al , supra) using the same parameters discussed above for derivative nucleic acid sequences A % amino acid sequence identity value is determined by the number of matching identical ammo acids dπ ided by the sequence length for which the percent identity is bemg reported "Percent (%) amino acid sequence similanty" is determined by doing the same calculation as for determining % ammo acid sequence identity, but including conservative ammo acid substitutions m addition to identical ammo acids in the computation A conservative ammo acid substitution is one in which an ammo acid is substituted for another ammo acid having similar properties such that the foldmg or activity of the protein is not significantly affected Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine, interchangeable hydrophobic ammo acids are leucine, isoleucme and valme, interchangeable polar ammo acids are glutamrne and asparagine, interchangeable basic ammo acids arginme, lysine and histidme, interchangeable acidic ammo acids aspartic acid and glutamic acid, and interchangeable small amino acids alanine, seπne, threonine, methionme, and glycme The fragment or derivative of a subjectprotein is preferably "functionally active" meaning that the subject protein deπvative or fragment exhibits one or more functional activities associated with a full-length, wild-type subject protein compπsing the ammo acid sequence of any of SEQ ID NOS 2, 4, or 6 As one example, a fragment or derivative may have antigemcity such that it can be used m immunoassays, for immunization, for inhibition of activity of a subject protein, etc, as discussed further below regarding generation of antibodies to subject proteins Preferably, a functionally active fragment or deπvative of a subject protein is one that displays one or more biological activities associated with a subject protein, such as enzymatic activity For purposes herein, functionally active fragments also include those fragments that exhibit one or more structural features of a subject protein, such as an ATP/GTP binding domain The functional activity of the subject proteins, derivatives and fragments can be assayed by various methods known to one skilled in the art (Cuπent Protocols in Protein Science (1998) Cohgan et al , eds , John Wiley & Sons, Inc , Somerset, New Jersey) In a prefeπed method, which is described m detail below, a model organism, such as Drosophila, is used in genetic studies to assess the phenotypic effect of a fragment or derivative (I e a mutant subject protem) Deπvatives of the subject protems can be produced by various methods known in the art The manipulations that result m their production can occur at the gene or protein level For example, a cloned subject gene sequence can be cleaved at appropπate sites with restπction endonuclease(s) (Wells et α/ , Phιlos Trans R Soc London SerA (1986) 317 415), followed by further enzymatic modification if desired, isolated, and hgated in vitro, and expressed to produce the desired derivative Alternatively, a subject gene can be mutated in vitro or in vivo, to create and/or destroy translation, initiation, and or termination sequences, or to create variations in coding regions and/or to form new restriction endonuclease sites or destroy preexistmg ones, to facilitate further in vitro modification A vaπety of mutagenesis techniques are known in the art such as chemical mutagenesis, in vitro site-directed mutagenesis (Carter et al , Nucl Acids Res (1986) 13 4331), use of TAB ® linkers (available from Pharmacia and Upjohn, Kalamazoo, MI), etc At the protein level, manipulations mclude post translational modification, e g glycosylation, acetylation, phosphorylation, amidation, derivatization by known protectmg blockmg groups, proteolytic cleavage, linkage to an antibody molecule or other cellular hgand, etc Any of numerous chemical modifications may be earned out by known technique (e g specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH , acetylation, formylation, oxidation, reduction, metabolic synthesis in the presence of tumcamycm, etc ) Derivative protems can also be chemically synthesized by use of a peptide synthesizer, for example to introduce nonclassical amino acids or chemical ammo acid analogs as substitutions or additions into a subject protein sequence Chimeric or fusion protems can be made comprising a subject protein or fragment thereof (preferably compnsing one or more structural or functional domains of a subject protein) joined at its ammo- or carboxy-terminus via a peptide bond to an ammo acid sequence of a different protein Chimeric proteins can be produced by any known method, including recombinant expression of a nucleic acid encoding the protein (compπsing a coding sequence encoding a subject protein joined m- frame to a coding sequence for a different protein), hgating the appropriate nucleic acid sequences encoding the desired ammo acid sequences to each other in the proper coding frame, and expressing the chimeric product, and protein synthetic techniques, e g by use of a peptide synthesizer dmHelicase protein In some embodiments, the invention provides dmHelicase protems, or fragments or derivatives thereof In other embodiments, a dmHelicase protein or fragment of the invention comprises an ammo acid sequence of at least about 24, at least about 26, at least about 29, at least about 34, at least about 50, at least about 75, at least about 80, at least about 100. at least about 150, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400, at least about 450, or at least about 475 contiguous ammo acids of the sequence set forth in SEQ ID NO 2, up to the entire amino acid sequence as set forth m SEQ ID NO 2 In one prefeπed embodiment, a subject protein derivative shares at least 80% sequence identity or similanty, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% sequence identity or similarity with a contiguous stretch of at least 25 ammo acids, preferably at least 50 ammo acids, more preferably at least 100 amino acids, and in some cases, the entire length of SEQ ID NO 2 In another embodiment, a subject protein derivative may consist of or comprise a sequence that shares 100% similanty with any contiguous stretch of at least 49 amino acids, preferably at least 51 ammo acids, more preferably at least 54 ammo acids, and most preferably at least 59 ammo acids of SEQ ID NO 2 In a preferred embodiment, the dmHelicase protem or derivative thereof compnses ammo acid residues 73-80, which is a putative ATP/GTP-bmding site motif Another preferred derivative of dmHelicase protein consists of or comprises a sequence of at least 26 ammo acids that share 100% similanty with an equivalent number of contiguous ammo acids of residues of SEQ ID NO 2 Prefeπed fragments of dmHelicase proteins consist or compnse at least 24, preferably at least 26, more preferably at least 29, and most preferably at least 34 contiguous amino acids of residues 187- 236 of SEQ ID N0 2 dmPITP proteins In some embodiments, the mvention provides dmPITP protems. or fragments or derivatives thereof In other embodiments, a dmPTIP protein of fragment of the invention comprises an ammo acid sequence of at least about 14, at least about 16, at least about 19, at least about 24, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 250, or at least about 270 contiguous amino acids of the sequence set forth in SEQ ID NO 4, up to the entire amino acid sequence as set forth in SEQ ID NO 4 In one prefeπed embodiment, a dmPITP protein derivative shares at least 80% sequence identity or similanty, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% sequence identity or similarity with a contiguous stretch of at least 25 amino acids, preferably at least 50 amino acids, more preferably at least 100 ammo acids, and m some cases, the entire length of SEQ ID NO 4 In another embodiment, the dmPITP protein derivative may consist of or compnse a sequence that shares 100% similarity with any contiguous stretch of at least 27 amino acids, preferably at least 29 ammo acids, more preferably at least 32 ammo acids, and most preferably at least 37 ammo acids of SEQ ID NO 4 dmSPL protems In some embodiments, the invention provides dmSPLl proteins, or fragments or derivatives thereof In some embodiments, a dmSPL protein or fragment of the invention comprises an ammo acid sequence of at least about 15, at least about 17, at least about 20, at least about 25, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400. at least about 450, at least about 500, or at least about 545 contiguous ammo acids of the sequence set forth m SEQ ID NO 6 In one prefeπed embodiment, a dmSPLl protein derivative shares at least 80% sequence identity or similanty, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% sequence identity or similarity with a contiguous stretch of at least 25 ammo acids, preferably at least 50 amino acids, more preferably at least 100 ammo acids, and in some cases, the entire length of SEQ ID NO 6 In another embodiment, the dmSPLl protein derivative may consist of or compπse a sequence that shares 100% similanty with any contiguous stretch of at least 36 ammo acids, preferably at least 38 amino acids, more preferably at least 41 ammo acids, and most preferably at least 46 amino acids of SEQ ID NO 6 Prefeπed derivatives of dmSPLl consist of or compπse an ammo acid sequence that has at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% sequence identity or sequence similarity with any of amino acid residues 1 -299 and 317-545, which are the likely extracellular or intracellular domains Gene Regulatory Elements of the Subject Nucleic Acid Molecules The invention further provides gene regulatory DNA elements, such as enhancers or promoters that control transcription of the subject nucleic acid molecules Such regulatory elements can be used to identify tissues, cells, genes and factors that specifically control production of a subject protein Analyzing components that are specific to a particular subject protein function can lead to an understanding of how to manipulate these regulatory processes, especially for pesticide and therapeutic applications, as well as an understanding of how to diagnose dysfunction in these processes Gene fusions with the subject regulatory elements can be made For compact genes that have relatively few and small intervening sequences, such as those described herein for Drosophila, it is typically the case that the regulatory elements that control spatial and temporal expression patterns are found in the DNA immediately upstream of the coding region, extending to the nearest neighboring gene Regulatory regions can be used to construct gene fusions where the regulatory DNAs are operably fused to a coding region for a reporter protein whose expression is easily detected, and these constructs are introduced as transgenes into the animal of choice An entire regulatory DNA region can be used, or the regulatory region can be divided into smaller segments to identify sub-elements that might be specific for controlling expression a given cell type or stage of development Reporter proteins that can be used for construction of these gene fusions include E coli beta-galactosidase and green fluorescent protein (GFP) These can be detected readily in situ, and thus are useful for histological studies and can be used to sort cells that express a subject protein (O'Kane and Gehπng PNAS (1987) 84(24) 9123-9127, Chalfie et al, Science (1994) 263 802-805; and Cumberledge and Krasnow (1994) Methods in Cell Biology 44: 143-159). Recombin∑ se proteins, such as FLP or ere, can be used in controlling gene expression through site-specific recombination (Golic and Lindquist (1989) Cell 59(3):499-509; White et al, Science (1996) 271 :805-807). Toxic proteins such as the reaper and hid cell death proteins, are useful to specifically ablate cells that normally express a subject protein in order to assess the physiological function of the cells (Kingston, In Cuπent Protocols in Molecular Biology (1998) Ausubel et al, John Wiley & Sons, Inc. sections 12.0.3-12.10) or any other protein where it is desired to examine the function this particular protein specifically in cells that synthesize a subject protein. Alternatively, a binary reporter system can be used, similar to that described further below, where a subject regulatory element is operably fused to the coding region of an exogenous transcriptional activator protein, such as the GAL4 or tTA activators described below, to create a subject regulatory element "driver gene". For the other half of the binary system the exogenous activator controls a separate "target gene" containing a coding region of a reporter protein operably fused to a cognate regulatory element for the exogenous activator protein, such as UAS G or a tTA-response element, respectively. An advantage of a binary system is that a single driver gene construct can be used to activate transcription from preconstructed target genes encoding different reporter proteins, each with its own uses as delineated above. Subject regulatory element-reporter gene fusions are also useful for tests of genetic interactions, where the objective is to identify those genes that have a specific role in controlling the expression of subject genes, or promoting the growth and differentiation of the tissues that expresses a subject protein. Subject gene regulatory DNA elements are also useful in protein-DNA binding assays to identify gene regulatory proteins that control the expression of subject genes. The gene regulatory proteins can be detected using a variety of methods that probe specific protein-DNA interactions well known to those skilled in the art (Kingston, supra) including in vivo footprinting assays based on protection of DNA sequences from chemical and enzymatic modification within living or permeabilized cells; and in vitro footprinting assays based on protection of DNA sequences from chemical or enzymatic modification using protein extracts, nitrocellulose filter-binding assays and gel electrophoresis mobility shift assays using radioactively labeled regulatory DNA elements mixed with protein extracts. Candidate gene regulatory proteins can be purified using a combination of conventional and DNA-affinity purification techniques. Molecular cloning strategies can also be used to identify proteins that specifically bind subject gene regulatory DNA elements. For example, a Drosophila cDNA library in an expression vector, can be screened for cDNAs that encode dmHelicase gene regulatory element DNA-binding activity. Similarly, the yeast "one-hybrid" system can be used (Li and Herskowitz, Science (1993) 262 1870-1874, Luo et al , Biotechniques (1996) 20(4) 564-568, Vidal et al , PNAS (1996) 93(19) 10315-10320) dmHelicase regulatory elements In some embodiments, the invention provides dmHelicase regulatory elements that reside withm nucleotides 1 to 161 of SEQ ID NO 1 Preferably at least 20, more preferably at least 25 , and most preferably at least 50 contiguous nucleotides withm nucleotides 1 to 161 of SEQ ID NO 1 are used dmPITP regulatory elements In some embodiments, the invention provides dmPITP gene regulatory elements that reside with nucleotides 1 to 182 of SEQ ID NO 3 Preferably at least 20, more preferably at least 25, and most preferably at least 50 contiguous nucleotides within nucleotides 1 to 182 of SEQ ID NO 3 are used dmSPL regulatory elements In some embodiments, the invention provides dmSPLl gene regulatory elements, that reside withm nucleotides 1 to 109 of SEQ ID NO 5 Preferably at least 20, more preferably at least 25, and most preferably at least 50 contiguous nucleotides within nucleotides 1 to 109 of SEQ ID NO 5 are used Antibodies to Subject Proteins The subject proteins, fragments thereof, and derivatives thereof may be used as an lmmunogen to generate monoclonal or polyclonal antibodies and antibody fragments or derivatives (e g chimeric, single chain, Fab fragments) For example, fragments of a subject protein, preferably those identified as hydrophihc, are used as lmmunogens for antibody production using art-known methods such as by hybndomas, production of monoclonal antibodies in germ-free animals (PCT US90/02545), the use of human hybndomas (Cole et al , PNAS ( 1983) 80 2026-2030, Cole et al , in Monoclonal Antibodies and Cancer Therapy (1985) Alan R Liss, pp 77-96), and production of humanized antibodies (Jones et al , Nature (1986) 321 522-525, U S Pat 5,530,101) In a particular embodiment, subject polypeptide fragments provide specific antigens and/or lmmunogens, especially when coupled to earner proteins For example, peptides are covalently coupled to keyhole limpet antigen (KLH) and the conjugate is emulsified m Freund's complete adjuvant Laboratory rabbits are immunized according to conventional protocol and bled The presence of specific antibodies is assayed by solid phase lmmunosorbent assays using immobilized coπespondmg polypeptide Specific activity or function of the antibodies produced may be determined by convenient in vitro, cell-based, or in vivo assays e g in vitro binding assays, etc Bmdmg affinity may be assayed by determination of equilibrium constants of antigen-antibody association (usually at least about 10 7 M "1 , preferably at least about 10 8 M "1 , more preferably at least about lO' M "1 ) Identification of Molecules that Interact with a Subject Protein A variety of methods can be used to identify or screen for molecules, such as proteins or other molecules, that interact with a subject protein, or denvatives or fragments thereof The assays may employ purified protein, or cell lines or model organisms such as Drosophila and C elegans, that have been genetically engineered to express a subject protein Suitable screening methodologies are well known in the art to test for protems and other molecules that interact with a subject gene and protem (see e g , PCT International Publication No WO 96/34099) The newly identified interactmg molecules may provide new targets for pharmaceutical or pesticidal agents Any of a variety of exogenous molecules, both naturally occurnng and/or synthetic (e g , libraries of small molecules or peptides, or phage display hbraπes), may be screened for binding capacity In a typical binding experiment, a subject protein or fragment is mixed with candidate molecules under conditions conducive to binding, sufficient time is allowed for any bmdmg to occur, and assays are performed to test for bound complexes Assays to find interacting proteins can be performed by any method known in the art, for example, lmmunoprecipitation with an antibody that binds to the protein in a complex followed by analysis by size fractionation of the lmmunoprecipitated proteins (e g by denaturing or nondenaturmg polyacrylamide gel electrophoresis), Western analysis, non-denaturmg gel electrophoresis, two-hybrid systems (Fields and Song, Nature (1989) 340 245-246, U S Pat NO 5,283,173, for review see Brent and Fmley, Annu Rev Genet (1977) 31 663-704), etc Immunoassays Immunoassays can be used to identify proteins that interact with or bind to a subject protein Various assays are available for testing the ability of a protein to bind to or compete with binding to a wild-type subject protein or for binding to an anti- subject protein antibody Suitable assays include radioimmunoassays, ELISA (enzyme linked lmmunosorbent assay), lmmunoradiometπc assays, gel diffusion precipitin reactions, lmmunodiffusion assays, in situ immunoassays (e g , using colloidal gold, enzyme or radioisotope labels), western blots, precipitation reactions, agglutination assays (e g , gel agglutination assays, hemagglutination assays), complement fixation assays, lmmunofluorescence assays, protein A assays, lmmunoelectrophoresis assays, etc Identification of Potential Pesticide or Drug Targets Once new target genes or target mteracting genes are identified, they can be assessed as potential pesticide or drug targets, or as potential biopesticides Further, transgenic plants that express subject protems can be tested for activity against insect pests (Estruch et al , Nat Biotechnol (1997) 15(2) 137-141) The subject protems are validated pesticide targets, since disruption of the Drosophila the subject genes results m lethality when homozygous The mutation to lethality of these gene indicates that drugs that agonize or antagonize the gene product may be effective pesticidal agents As used herein, the term "pesticide" refers generally to chemicals, biological agents, and other compounds that kill, paralyze, sterilize or otherwise disable pest species m the areas of agricultural crop protection, human and animal health Exemplary pest species include parasites and disease vectors such as mosquitoes, fleas, ticks, parasitic nematodes, chiggers, mites, etc Pest species also include those that are eradicated for aesthetic and hygienic purposes (e g ants, cockroaches, clothes moths, flour beetles, etc ), home and garden applications, and protection of structures (including wood boπng pests such as termites, and marine surface fouling organisms) Pesticidal compounds can include traditional small organic molecule pesticides (typified by compound classes such as the organophosphates, pyrethroids, carbamates, and organochloπnes, benzoylureas, etc ) Other pesticides include proteinaceous toxins such as the Bacillus thuringiensis Crytoxms (Gill et al , Annu Rev Entomol (1992) 37 615-636) and Photorabdus luminescent toxins (Bowden et al , Science (1998) 280 2129-2132), and nucleic acids such as subject dsRNA or antisense nucleic acids that interferes with activity of a subject nucleic acid molecule Pesticides can be delivered by a variety of means including direct application to pests or to their food source In addition to direct application, toxic proteins and pesticidal nucleic acids (e g dsRNA) can be administered using biopesticidal methods, for example, by viral infection with nucleic acid or by transgenic plants that have been engmeered to produce interfering nucleic acid sequences or encode the toxic protein, which are mgested by plant-eating pests Putative pesticides, drugs, and molecules can be applied onto whole insects, nematodes, and other small invertebrate metazoans, and the ability of the compounds to modulate (e g block or enhance) activity of a subject protein can be observed Alternatively, the effect of various compounds on a subject protein can be assayed using cells that have been engineered to express one or more subject protems and associated protems Assays of Compounds on Worms In a typical worm assay, th3 compounds to be tested are dissolved in DMSO or other organic solvent, mixed with a bacterial suspension at various test concentrations, preferably OP50 strain of bacteria (Brenner, Genetics (1974) 110:421-440), and supplied as food to the worms. The population of worms to be treated can be synchronized larvae (Sulston and Hodgkin, in the nematode C. elegans (1988), supra) or adults or a mixed-stage population of animals. Adult and larval worms are treated with different concentrations of compounds, typically ranging from 1 mg/ml to 0.001 mg/ml. Behavioral abeπations, such as a decrease in motility and growth, and morphological abeπations, sterility, and death are examined in both acutely and chronically treated adult and larval worms. For the acute assay, larval and adult worms are examined immediately after application of the compound and re-examined periodically (every 30 minutes) for 5-6 hours. Chronic or long-term assays are performed on worms and the behavior of the treated worms is examined every 8-12 hours for 4-5 days. In some circumstances, it is necessary to reapply the pesticide to the treated worms every 24 hours for maximal effect. Assays of Compounds on Insects Potential insecticidal compounds can be administered to insects in a variety of ways, including orally (including addition to synthetic diet, application to plants or prey to be consumed by the test organism), topically (including spraying, direct application of compound to animal, allowing animal to contact a treated surface), or by injection. Insecticides are typically very hydrophobic molecules and must commonly be dissolved in organic solvents, which are allowed to evaporate in the case of methanol or acetone, or at low concentrations can be included to facilitate uptake (ethanol, dimethyl sulfoxide). The first step in an insect assay is usually the determination of the minimal lethal dose (MLD) on the insects after a chronic exposure to the compounds. The compounds are usually diluted in DMSO, and applied to the food surface bearing 0-48 hour old embryos and larvae. In addition to MLD, this step allows the determination of the fraction of eggs that hatch, behavior of the larvae, such as how they move /feed compared to untreated larvae, the fraction that survive to pupate, and the fraction that eclose (emergence of the adult insect from puparium). Based on these results more detailed assays with shorter exposure times may be designed, and larvae might be dissected to look for obvious morphological defects. Once the MLD is determined, more specific acute and chronic assays can be designed. In a typical acute assay, compounds are applied to the food surface for embryos, larvae, or adults, and the animals are observed after 2 hours and after an overnight incubation. For application on embryos, defects in development and the percent that survive to adulthood are determined. For larvae, defects m behavior, locomotion, and molting may be observed For application on adults, behavior and neurological defects are observed, and effects on fertility are noted For a chrome exposure assay, adults are placed on vials containing the compounds for 48 hours, then transfeπed to a clean container and observed for fertility, neurological defects, and death Assay of Compounds using Cell Cultures Compounds that modulate (e g block or enhance) a subject protein's activity may also be assayed using cell culture For example, various compounds added to cells expressing a subject protem may be screened for their ability to modulate the activity of subject genes based upon measurements of a biological activity of a subject protein Assays for changes in a biological activity of a subject protein can be performed on cultured cells expressing endogenous normal or mutant subject protein Such studies also can be performed on cells transfected with vectors capable of expressing the subject protein, or functional domains of one of the subject protein, m normal or mutant form In addition, to enhance the signal measured m such assays, cells may be cotransfected with genes encoding a subject protein Alternatively, cells expressing a subject protein may be lysed, the subject protein purified, and tested in vitro using methods known m the art (Kanemaki M , et al , J Biol Chem, 1999 274 22437- 22444) Compounds that selectively modulate a subject protein are identified as potential pesticide and drug candidates having specificity for the subject protein Identification of small molecules and compounds as potential pesticides or pharmaceutical compounds from large chemical hbraπes requires high-throughput screening (HTS) methods (Bolger, Drug Discovery Today (1999) 4 251-253) Several of the assays mentioned herein can lend themselves to such screemng methods For example, cells or cell lines expressing wild type or mutant subject protem or its fragments, and a reporter gene can be subjected to compounds of interest, and depending on the reporter genes, interactions can be measured using a variety of methods such as color detection, fluorescence detection (e g GFP). autoradiography, scintillation analysis, etc Subject Nucleic Acids as Biopesticides Subject nucleic acids and fragments thereof, such as antisense sequences or double-stranded RNA (dsRNA), can be used to inhibit subject nucleic acid molecule function, and thus can be used as biopesticides Methods of using dsRNA interference are described in published PCT application WO 99/32619 The biopesticides may comprise the nucleic acid molecule itself, an expression construct capable of expressing the nucleic acid, or organisms transfected with the expression construct The biopesticides may be applied directly to plant parts or to soil surrounding the plants (e g to access plant parts growing beneath ground level), or directly onto the pest Biopesticides compπsmg a subject nucleic acid may be prepared in a suitable vector for delivery to a plant or animal For generatmg plants that express the subject nucleic acids, suitable vectors include Agrobacterium tumefaciens Ti plasmid-based vectors (Horsch et al , Science (1984) 233 496-89, Fraley et al , Proc Natl Acad Sci USA (1983) 80 4803), and recombinant cauliflower mosaic virus (Hohn et al , 1982, In Molecular Biology of Plant Tumors, Academic Press, New York, pp 549-560, U S Patent No 4,407,956 to Howell) Retrovirus based vectors are useful for the introduction of genes into vertebrate animals (Burns et al , Proc Natl Acad Sci USA (1993) 90 8033-37) Transgenic insects can be generated using a transgene compπsing a subject gene operably fused to an appropπate mducible promoter For example, a tTA-responsive promoter may be used in order to direct expression of a subject protem at an appropriate time in the life cycle of the insect In this way, one may test efficacy as an insecticide in, for example, the larval phase of the life cycle (I e when feeding does the greatest damage to crops) Vectors for the introduction of genes into insects include P element (Rubm and Spradlmg, Science (1982) 218 348-53, U S Pat No 4,670,388), "hermes" (O'Brochta et al , Genetics (1996) 142 907-914), "minos" (U S Pat No 5,348,874), "mariner" (Robertson, Insect Physiol (1995) 41 99-105), and "sleeping beauty"(Ivιcs et al . Cell (1997) 91(4) 501-510), "piggyBac" (Thibault et al , Insect Mol Biol (1999) 8(1) 119-23), and "hobo" (Atkmson et al , Proc Natl Acad Sci U S A (1993) 90 9693-9697) Recombinant virus systems for expression of toxic proteins in infected insect cells are well known and include Semhki Forest virus (DiCiommo and Bremner, J Biol Chem (1998) 273 18060-66), recombinant smdbis virus (Higgs et al , Insect Mol Biol (1995) 4 97- 103, Seabaugh et al , Virology (1998) 243 99-112), recombinant pantropic retrovirus (Matsubara et al , Proc Natl Acad Sci USA (1996) 93 6181-85, Jordan et al , Insect Mol Biol (1998) 7 215-22), and recombinant baculovirus (Cory and Bishop, Mol Biotechnol (1997) 7(3) 303-13, U S Patent No 5,470,735, U S Patent Nos 5,352,451, U S Patent No 5, 770, 192, U S Patent No 5,759,809, U S Patent No 5,665,349, and U S Patent No 5,554,592) Generation and Genetic Analysis of Animals and Cell Lines with Altered Expression of a Subject Gene Both genetically modified animal models (I e in vivo models), such as C elegans and Drosophila, and in vitro models such as genetically engineered cell lines expressing or mis-expressmg subject pathway genes, are useful for the functional analysis of these proteins Model systems that display detectable phenotypes, can be used for the identification and characteπzation of subject pathway genes or other genes of interest and/or phenotypes associated with the mutation or mis-expression of subject pathway protem The term "mis-expression" as used herein encompasses mis-expression due to gene mutations Thus, a mis-expressed subject pathway protem may be one havmg an am o acid sequence that differs from wild-type (1 e it is a derivative of the normal protem) A mis-expressed subject pathway protem may also be one in which one or more ammo acids have been deleted, and thus is a "fragment" of the normal protem As used herein, "mis-expression" also includes ectopic expression (e g by altering the normal spatial or temporal expression), over-expression (e g by multiple gene copies), underexpression, non-expression (e g by gene knockout or blocking expression that would otherwise normally occur), and further, expression in ectopic tissues As used in the following discussion concerning in vivo and in vitro models, the term "gene of interest" refers to a subject pathway gene, or any other gene involved in regulation or modulation, or downstream effector of the subject pathway The in vivo and in vitro models may be genetically engineered or modified so that they 1) have deletions and/or insertions of one or more subject pathway genes, 2) harbor interfering RNA sequences denved from subject pathway genes, 3) have had one or more endogenous subject pathway genes mutated (e g contain deletions, insertions, reaπangements, or point mutations in subject gene or other genes in the pathway), and/or 4) contain transgenes for mis-expression of wild-type or mutant forms of such genes Such genetically modified in vivo and in vitro models are useful for identification of genes and protems that are involved m the synthesis, activation, control, etc of subject pathway gene and/or gene products, and also downstream effectors of subject function, genes regulated by subject, etc The newly identified genes could constitute possible pesticide targets (as judged by animal model phenotypes such as non-viability, block of normal development, defective feeding, defective movement, or defective reproduction) The model systems can also be used for testing potential pesticidal or pharmaceutical compounds that interact with the subject pathway, for example by administering the compound to the model system using any suitable method (e g direct contact, ingestion, injection, etc ) and observing any changes m phenotype, for example defective movement, lethality, etc Various genetic engineering and expression modification methods which can be used are well-known in the art, including chemical mutagenesis, transposon mutagenesis, antisense RNAi, dsRNAi, and transgene-mediated mis- expression Generating Loss-of-function Mutations by Mutagenesis Loss-of-function mutations in an invertebrate metazoan subject gene can be generated by any of several mutagenesis methods known in the art (Ashburner, In Drosophila melanogaster A Laboratory Manual (1989) , Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press pp 299-418, Fly pushing The Theory and Practice of Drosophila melanogaster Genetics (1997) Cold Spring Harbor Press, Plainview, NY, The nematc de C elegans (1988) Wood, Ed , Cold Sprmg Harbor Laboratory Press, Cold Spring harbor, New York) Techniques for producmg mutations m a gene or genome include use of radiation ( e g , X-ray, UV, or gamma ray), chemicals (e g , EMS, MMS, ENU, formaldehyde, etc ), and insertional mutagenesis by mobile elements including dysgenesis induced by transposon insertions, or transposon-mediated deletions, for example, male recombmation, as descnbed below Other methods of altering expression of genes include use of transposons (e g , ? element, EP-type "overexpression trap" element, manner element, piggyBac transposon, hermes, minos, sleepmg beauty, etc ) to misexpress genes, antisense, double-stranded RNA interference, peptide and RNA aptamers, directed deletions, homologous recombination, dominant negative alleles, and intrabodies Transposon insertions lying adjacent to a gene of interest can be used to generate deletions of flanking genomic DNA, which if induced m the germhne, are stably propagated in subsequent generations The utility of this technique in generating deletions has been demonstrated and is well- known in the art One version of the technique using collections of P element transposon induced recessive lethal mutations (P iethals) is particularly suitable for rapid identification of novel, essential genes in Drosophila (Cooley et al , Science (1988) 239 1121-1128, Spralding et al , PNAS (1995) 92 0824-10830) Since the sequence of the P elements are known, the genomic sequence flanking each transposon insert is determined either by plasmid rescue (Hamilton et al , PNAS (1991) 88 2731-2735) or by inverse polymerase chain reaction, using well-established techniques (Rehm, http //www fruitfly org/methods/) The subject genes were identified from a P lethal screen Disruption of the Drosophila subject gene results m lethality when homozygous, indicating that this protein is critical for cell function and the survival of insects The mutation to lethality of this gene indicates that drugs which agonize or antagonize the encoded subject protein will be effective msecticidal agents and that this class of proteins are excellent targets for drug screening and discovery A more recent version of the transposon insertion technique in male Drosophila using P elements is known as P-mediated male recombmation (Preston and Engels, Genetics (1996) 144 161 1- 1638) Generating Loss-of-function Phenotypes Using RNA-based Methods The subject genes may be identified and/or charactenzed by generating loss-of-function phenotypes in animals of mterest through RNA-based methods, such as antisense RNA (Schubiger and Edgar, Methods in Cell Biology (1994) 44 697-713) One form of the antisense RNA method involves the injection of embryos with an antisense RNA that is partially homologous to the gene of interest (m this case the subject gene) Another form of the antisense RNA method involves expression of an antisense RNA partially homologous to the gene of mterest by operably joining a portion of the gene of mterest in the antisense oπentation to a powerful promoter that can drive the expression of large quantities of antisense RNA, either generally throughout the ani al or in specific tissues Antisense RNA-generated loss-of-function phenotypes have been reported previously for several Drosophila genes including cactus, pecanex, and Kruppel (LaBonne et al , Dev Biol (1989) 136(1) 1-16, Schuh and Jackie, Genome (1989) 31(1) 422-425, Geisler et al , Cell (1992) 71(4) 613-621) Loss-of-function phenotypes can also be generated by cosuppression methods (Bingham Cell (1997) 90(3) 385-387, Smyth, Curr Biol (1997) 7(12) 793-795, Que and Jorgensen, Dev Genet (1998) 22(1) 100-109) Cosuppression is a phenomenon of reduced gene expression produced by expression or injection of a sense strand RNA corresponding to a partial segment of the gene of interest Cosuppression effects have been employed extensively in plants and C elegans to generate loss-of- function phenotypes, and there is a single report of cosuppression m Drosophila, where reduced expression of the Adh gene was induced from a white-Adh transgene using cosuppression methods (Pal- Bhadra et al , Cell (1997) 90(3) 479-490) Another method for generating loss-of-function phenotypes is by double-stranded RNA interference (dsRNAi) This method is based on the interfeπng properties of double-stranded RNA derived from the coding regions of gene, and has proven to be of great utility in genetic studies of C elegans (Fire et al , Nature (1998) 391 806-811), and can also be used to generate loss-of-function phenotypes m Drosophila (Kennerdell and Carthew, Cell (1998) 95 1017-1026, Misquitta and Patterson PNAS (1999) 96 1451-1456) In one example of this method, complementary sense and antisense RNAs derived from a substantial portion of a gene of interest, such as a subject gene, are synthesized in vitro The resulting sense and antisense RNAs are annealed in an injection buffer, and the double-stranded RNA injected or otherwise introduced into animals (such as m their food or by soaking in the buffer containing the RNA) Progeny of the injected animals are then inspected for phenotypes of interest (PCT publication no W099/32619) Generating Loss-of-function Phenotypes Using Peptide and RNA Aptamers Additional methods that can be used for generating loss-of-function phenotypes include use of peptide aptamers that act as dominant inhibitors of protein function (Kolonin and Finley, PNAS (1998) 95 14266-14271, Xu et al , PNAS (1997) 94 12473-12478, Hoogenboom et al . Immunotechnology (1998) 4 1-20), RNA aptamers (Good et al , Gene Therapy (1997) 4 45-54, Ellington et al , Biotechnol Annu Rev (1995) 1 185-214, Bell e/ al . J Biol Chem (1998) 273 14309-14314, Shi et al , Proc Natl Acad Sci USA (1999) 96 10033-10038), and intrabodies (Chen et al , Hum Gen Ther (1994) 5 595-601, Hassanzadeh et al , Febs Lett (1998) 16 75-86) Generating Loss of Function Phenotypes Using Intrabodies Intracellularly expressed antibodies, or intrabodies, are single-chain antibody molecules designed to specifically bind and inactivate target molecules inside cells Intrabodies have been used in cell assays and in whole organisms such as Drosophila (Chen et al , Hum Gen Ther (1994) 5 595- 601, Hassanzadeh et al , Febs Lett (1998) 16(1, 2) 75-80 and 81-86) Inducible expression vectors can be constructed with mtrabodies that react specifically with a subject protem These vectors can be introduced into model organisms and studied in the same manner as descnbed above for aptamers Transgenesis Typically, transgenic animals are created that contain gene fusions of the coding regions of a subject gene (from either genomic DNA or cDNA) or genes engineered to encode antisense RNAs, cosuppression RNAs, interfering dsRNA, RNA aptamers, peptide aptamers, or intrabodies operably joined to a specific promoter and transcriptional enhancer whose regulation has been well characteπzed, preferably heterologous promoters/enhancers (I e promoters/enhancers that are non-native to a subject pathway genes being expressed) Methods are well known for incorporating exogenous nucleic acid sequences into the genome of animals or cultured cells to create transgenic animals or recombinant cell lines For invertebrate animal models, the most common methods involve the use of transposable elements There are several suitable transposable elements that can be used to incorporate nucleic acid sequences mto the genome of model orgamsms Transposable elements are particularly useful for inserting sequences into a gene of interest so that the encoded protein is not properly expressed, creatmg a "knock-out" animal having a loss-of- function phenotype Techniques are well-established for the use of P element in Drosophila (Rubm and Spradlmg, Science (1982) 218 348-53, U S Pat No 4,670,388) and Tel in C elegans (Zwaal et al , Proc Natl Acad Sci U S A (1993) 90 7431-7435, and Caenorhabditis elegans Modern Biological Analysis of an Orgamsm (1995) Epstein and Shakes, Eds ) Other Tcl-hke transposable elements can be used such as mmos, mariner and sleeping beauty Additionally, transposable elements that function in a vaπety of species, have been identified, such as PiggyBac (Thibault et al , Insect Mol Biol (1999) 8(1) 119-23), hobo, and hermes P elements, or marked P elements, are prefeπed for the isolation of loss-of-function mutations in Drosophila genes because of the precise molecular mappmg of these genes, depending on the availability and proximity of preexistmg P element insertions for use as a localized transposon source (Hamilton and Zinn, Methods in Cell Biology (1994) 44 81-94, and Wolfner and Goldberg, Methods in Cell Biology (1994) 44 33-80) Typically, modified P elements are used which contain one or more elements that allow detection of animals containing the P element Most often, marker genes are used that affect the eye color oi Drosophila, such as deπvatives of the Drosophila white or rosy genes (Rubm and Spradlmg, Science (1982) 218(4570) 348-353, and Klemenz et al , Nucleic Acids Res (1987) 15(10) 3947-3959) However, in principle, any gene can be used as a marker that causes a reliable and easily scored phenotypic change in transgenic animals Vaπous other markers include bacterial plasmid sequences having selectable markers such as ampicillm resistance (Steller and Piπotta, EMBO J (1985) 4 167- 171 ), and lacZ sequences fused to a weak general promoter to detect the presence of enhancers with a developmental expression pattern of interest (Bellen et al , Genes Dev (1989) 3(9) 1288-1300) Other examples of marked P elements useful for mutagenesis have been reported (Nucleic Acids Research (1998) 26 85-88, and http //flybase bio Indiana edu) Prefeπed methods of transposon mutagenesis in Drosophila employ the "local hopping" method described by Tower et al (Genetics (1993) 133 347-359) or generation of localized deletions from Drosophila lines carrying P insertions in the gene of interest using known methods (Kaiser, Bioassays (1990) 12(6),297-301. Harnessing the power oi Drosophila genetics, In Drosophila melanogaster Practical Uses in Cell and Molecular Biology, Goldstein and Fyrberg, Eds , Academic Press, Inc , San Diego, California) The prefeπed method of transposon mutagenesis m C elegans employs Tel transposable element (Zwaal et al, supra, Plasterk et al , supra) In addition to creating loss-of-function phenotypes, transposable elements can be used to incorporate the gene of mterest, or mutant or derivative thereof, as an additional gene into any region of an animal's genome resulting in mis-expression (including over-expression) of the gene A prefeπed vector designed specifically for misexpression of genes in transgenic Drosophila, is derived from pGMR (Hay et al , Development ( 1994) 120 2121-2129), is 9Kb long, and contains an origin of replication for E coli, an ampicillm resistance gene, P element transposon 3' and 5' ends to mobilize the inserted sequences, a White marker gene, an expression unit compπsing the TATA region of hsp70 enhancer and the 3 'untranslated region of α-tubuhn gene The expression unit contains a first multiple cloning site (MCS) designed for insertion of an enhancer and a second MCS located 500 bases downstream, designed for the insertion of a gene of interest As an alternative to transposable elements, homologous recombination or gene targeting techniques can be used to substitute a gene of interest for one or both copies of the animal's homologous gene The transgene can be under the regulation of either an exogenous or an endogenous promoter element, and be inserted as either a minigene or a large genomic fragment In one application, gene function can be analyzed by ectopic expression, usmg, for example, Drosophila (Brand et al , Methods in Cell Biology (1994) 44 635- 654) or C elegans (Mello and Fire, Methods in Cell Biology (1995) 48 451-482) Examples of well-characterized heterologous promoters that may be used to create the transgenic animals mclude heat shock promoters/enhancers, which are useful for temperature induced mis-expression, hi Drosophila, t lese include the hsp70 and hsp83 genes, and in C. elegans, include hsp 16-2 and hsp 16-41. Tissue spec fie promoters/enhancers are also useful, and in Drosophila, include eyeless (Mozer and Benzer, Development (1994) 120:1049-1058), sevenless (Bowtell et al, PNAS (1991) 88(15):6853-6857), and glass-responsive promoters/enhancers (Quiring et al, Science (1994) 265 :785-789) which are useful for expression in the eye; and enhancers/promoters derived from the dpp or vestigal genes which are useful for expression in the wing (Staehling-Hampton et al, Cell Growth Differ. (1994) 5(6):585-593; Kim et al, Nature (1996) 382:133-138). Finally, where it is necessary to restrict the activity of dominant active or dominant negative transgenes to regions where the pathway is normally active, it may be useful to use endogenous promoters of genes in the pathway, such as a subject protein pathway genes. In C. elegans, examples of useful tissue specific promoters/enhancers include the myo-2 gene promoter, useful for pharyngeal muscle-specific expression; the hlh-1 gene promoter, useful for body- muscle-specific expression; and the gene promoter, useful for touch-neuron-specific gene expression. In a prefeπed embodiment, gene fusions for directing the mis-expression of a subject pathway gene are incorporated into a transformation vector which is injected into nematodes along with a plasmid containing a dominant selectable marker, such as rol-6. Transgenic animals are identified as those exhibiting a roller phenotype, and the transgenic animals are inspected for additional phenotypes of interest created by mis-expression of a subject pathway gene. In Drosophila, binary control systems that employ exogenous DNA are useful when testing the mis-expression of genes in a wide variety of developmental stage-specific and tissue-specific patterns. Two examples of binary exogenous regulatory systems include the UAS/GAL4 system from yeast (Hay et al, PNAS (1997) 94(10):5195-5200; Ellis et al, Development (1993) 119(3):855-865); Brand and Peπimon (1993) Development 118(2):401-415), and the "Tet system" derived from E. coli (Bello et al, Development (1998) 125:2193-2202). Dominant negative mutations, by which the mutation causes a protein to interfere with the normal function of a wild-type copy of the protein, and which can result in loss-of-function or reduced- function phenotypes in the presence of a normal copy of the gene, can be made using known methods (Hershkowitz, Nature (1987) 329:219-222). Assays for Change in Gene Expression Various expression analysis techniques may be used to identify genes which are differentially expressed between a cell line or an animal expressing a wild type subject gene compared to another cell line or animal expressing a mutant subject gene. Such expression profiling techniques include differential display, serial analysis of gene expression (SAGE), transcript profiling coupled to a gene database query, nucleic acid aπay technology, subtractive hybridization, and proteome analysis (e g mass-spectrometry and two-dimensional protem gels) Nucleic acid array technology may be used to determine a global (1 e , genome-wide) gene expression pattern in a normal animal for compaπson with an animal havmg a mutation in a subject gene Gene expression profiling can also be used to identify other genes (or protems) that may have a functional relation to a subject (e g may participate m a signaling pathway with a subject gene) The genes are identified by detecting changes in their expression levels following mutation, 1 e , insertion, deletion or substitution in, or over-expression, under- expression, mis-expression or knock-out, of the dmHelicase gene Phenotypes Associated with Target Pathway Gene Mutations After isolation of model animals carrying mutated or mis-expressed subject pathway genes or inhibitory RNAs, ammals are carefully examined for phenotypes of interest For analysis of subject pathway genes that have been mutated (I e deletions, insertions, and/or point mutations) animal models that are both homozygous and heterozygous for the altered subject pathway gene are analyzed Examples of specific phenotypes that may be investigated include lethality, sterility, feeding behavior, perturbations m neuromuscular function including alterations m motility, and alterations m sensitivity to pesticides and pharmaceuticals Some phenotypes more specific to flies include alterations in adult behavior such as, flight ability, walking, grooming, phototaxis, mating or egg-laying, alterations in the responses of sensory organs, changes in the morphology, size or number of adult tissues such as, eyes, wings, legs, bnstles, antennae, gut, fat body, gonads, and musculature, larval tissues such as mouth parts, cuticles, internal tissues or imaginal discs, or larval behavior such as feeding, molting, crawling, or pupaπan formation, or developmental defects in any germhne or embryonic tissues Some phenotypes more specific to nematodes include locomotory, egg laying, chemosensation, male mating, and intestinal expulsion defects In various cases, single phenotypes or a combination of specific phenotypes in model organisms might point to specific genes or a specific pathway of genes, which facilitate the cloning process Genomic sequences containing a subject pathway gene can be used to confirm whether an existing mutant insect or worm line coπesponds to a mutation in one or more subject pathway genes, by rescuing the mutant phenotype Briefly, a genomic fragment contaimng the subject pathway gene of interest and potential flanking regulatory regions can be subcloned into any appropriate insect (such as Drosophila) or worm (such as C elegans) transformation vector, and mjected mto the animals For Drosophila, an appropπate helper plasmid is used in the injections to supply transposase for transposon- based vectors Resulting germhne transformants are crossed for complementation testing to an existing or newly created panel oi Drosophila or C elegans lines whose mutations have been mapped to the vicinity of the gene of interest (Fly Pushing: The Theory and Practice oi Drosophila Genetics, supra; and Caenorhabditis elegans: Modern Biological Analysis of an Organism (1995), Epstein and Shakes, eds.). If a mutant line is discovered to be rescued by this genomic fragment, as judged by complementation of the mutant phenotype, then the mutant line likely harbors a mutation in the subject pathway gene. This prediction can be further confirmed by sequencing the subject pathway gene from the mutant line to identify the lesion in the subject pathway gene. Identification of Genes That Modify a Subject Genes The characterization of new phenotypes created by mutations or misexpression in subject genes enables one to test for genetic interactions between subject genes and other genes that may participate in the same, related, or interacting genetic or biochemical pathway(s). Individual genes can be used as starting points in large-scale genetic modifier screens as described in more detail below. Alternatively, RNAi methods can be used to simulate loss-of-function mutations in the genes being analyzed. It is of particular interest to investigate whether there are any interactions of subject genes with other well- characterized genes, particularly genes involved in DNA unwinding. Genetic Modifier Screens A genetic modifier screen using invertebrate model organisms is a particularly prefeπed method for identifying genes that interact with subject genes, because large numbers of animals can be systematically screened making it more possible that interacting genes will be identified. In Drosophila, a screen of up to about 10,000 animals is considered to be a pilot-scale screen. Moderate-scale screens usually employ about 10,000 to about 50,000 flies, and large-scale screens employ greater than about 50,000 flies. In a genetic modifier screen, animals having a mutant phenotype due to a mutation in or misexpression of one or more subject genes are further mutagenized, for example by chemical mutagenesis or transposon mutagenesis. The procedures involved in typical Drosophila genetic modifier screens are well-known in the art (Wolfher and Goldberg, Methods in Cell Biology (1994) 44:33-80; and Karim et al, Genetics (1996) 143:315-329). The procedures used differ depending upon the precise nature of the mutant allele being modified. If the mutant allele is genetically recessive, as is commonly the situation for a loss-of-function allele, then most typically males, or in some cases females, which carry one copy of the mutant allele are exposed to an effective mutagen, such as EMS, MMS, ENU, triethylamine, diepoxyalkanes, ICR-170, formaldehyde, X-rays, gamma rays, or ultraviolet radiation. The mutagenized animals are crossed to animals of the opposite sex that also carry the mutant allele to be modified. In the case where the mutant allele being modified is genetically dominant, as is commonly the situation for ectopically expressed genes, wild type males are mutagenized and crossed to females carrying the mutant allele to be modified. The progeny of the mutagenized and crossed flies that exhibit either enhancement or suppression of the original phenotype are presumed to have mutations in other genes, called "modifier genes", that participate in the same phenotype-generating pathway. These progeny are immediately crossed to adults containing balancer chromosomes and used as founders of a stable genetic line. In addition, progeny of the founder adult are retested under the original screening conditions to ensure stability and reproducibility of the phenotype. Additional secondary screens may be employed, as appropriate, to confirm the suitability of each new modifier mutant line for further analysis. Standard techniques used for the mapping of modifiers that come from a genetic screen in Drosophila include meiotic mapping with visible or molecular genetic markers; male-specific recombination mapping relative to P-element insertions; complementation analysis with deficiencies, duplications, and lethal P-element insertions; and cytological analysis of chromosomal abeπations (Fly Pushing: Theory and Practice oi Drosophila Genetics, supra; Drosophila: A Laboratory Handbook, supra). Genes coπesponding to modifier mutations that fail to complement a lethal P-element may be cloned by plasmid rescue of the genomic sequence surrounding that P-element. Alternatively, modifier genes may be mapped by phenotype rescue and positional cloning (Sambrook et al, supra). Newly identified modifier mutations can be tested directly for interaction with other genes of interest known to be involved or implicated with a subject gene using methods described above. Also, the new modifier mutations can be tested for interactions with genes in other pathways that are not believed to be related to neuronal signaling (e.g. nanos in Drosophila). New modifier mutations that exhibit specific genetic interactions with other genes implicated in neuronal signaling, but not interactions with genes in unrelated pathways, are of particular interest. The modifier mutations may also be used to identify "complementation groups". Two modifier mutations are considered to fall within the same complementation group if animals carrying both mutations in trans exhibit essentially the same phenotype as animals that are homozygous for each mutation individually and, generally are lethal when in trans to each other (Fly Pushing: The Theory and Practice oi Drosophila Genetics, supra). Generally, individual complementation groups defined in this way coπespond to individual genes. When modifier genes are identified, homologous genes in other species can be isolated using procedures based on cross-hybridization with modifier gene DNA probes, PCR-based strategies with primer sequences derived from the modifier genes, and/or computer searches of sequence databases. For therapeutic applications related to the function of subject genes, human and rodent homologs of the modifier genes are of particular interest. For pesticide and other agricultural applications, homologs of modifier genes m msects and ara inids are of particular interest Insects, arachnids, and other orgamsms of mterest include, among others, sopoda, Diplopoda, Chilopoda, Symphyla, Thysanura, Collembola, Orthoptera, such as Scistocerca spp, Blittoidea, such as Blattella germanica, Dermaptera, Isoptera, Anoplura, Mallophaga, Thysanoptera, Heteroptera, Homoptera, mcluding Bemista tabaci, and Myzus spp , Lepidoptera including Plodiα inter punctellα, Pectinophorα gossypiellα, Plutellα spp , Helwthis spp , and Spodoptera species, Coleoptera such as Leptinotarsa, Diabrotica spp ,Anthonomus spp , and Tribohum spp , Hymenoptera, Diptera, including Anopheles spp , Siphonaptera, including Ctenocephahdes fehs, Arachnida, and Acannan, including Amblyoma americanum, and nematodes, including Meloidogyne spp , and Heterodera glycinii Although the above-described Drosophila genetic modifier screens are quite powerful and sensitive, some genes that interact with subject genes may be missed in this approach, particularly if there is functional redundancy of those genes This is because the vast majority of the mutations generated in the standard mutagenesis methods will be loss-of-function mutations, whereas gain-of- function mutations that could reveal genes with functional redundancy will be relatively rare Another method of genetic screening m Drosophila has been developed that focuses specifically on systematic gain-of-function genetic screens (Rorth et al , Development ( 1998) 125 1049- 1057) This method is based on a modular mis-expression system utilizing components of the GAL4 UAS system (descnbed above) where a modified P element, termed an "enhanced P" (EP) element, is genetically engineered to contain a GAL4-responsιve UAS element and promoter Any other transposons can also be used for this system The resulting transposon is used to randomly tag genes by msertional mutagenesis (similar to the method of P element mutagenesis descnbed above) Thousands of transgenic Drosophila strains, termed EP lines, can be generated, each containing a specific UAS-tagged gene This approach takes advantage of the preference of P elements to insert at the 5 '-ends of genes Consequently, many of the genes that are tagged by insertion of EP elements become operably fused to a GAL4-regulated promoter. and increased expression or mis-expression of the randomly tagged gene can be induced by crossing in a GAL4 driver gene Systematic gam-of-function genetic screens for modifiers of phenotypes induced by mutation or mis-expression of a subject gene can be performed by crossing several thousand Drosophila EP lmes individually mto a genetic background containing a mutant or mis-expressed subject gene, and further contammg an appropriate GAL4 driver transgene It is also possible to remobihze the EP elements to obtam novel insertions The progeny of these crosses are then analyzed for enhancement or suppression of the ongmal mutant phenotype as described above Those identified as having mutations that interact with the subject gene can be tested further to verify the reproducibility and specificity of this genetic interaction EP insertions that demonstrate a specific genetic mteraction with a mutant or mis-expressed subject gene, have a physically tagged new gene which can be identified and sequenced usmg PCR or hybπdization screening methods, allowing the isolation of the genomic DNA adjacent to the position of the EP element insertion EXAMPLES The following examples describe the isolation and cloning of the nucleic acid sequence of SEQ ID NOS 1, 3, and 5 and how these sequences, and derivatives and fragments thereof, as well as other pathway nucleic acids and gene products can be used for genetic studies to elucidate mechanisms of a pathway involving a subject protein as well as the discovery of potential pharmaceutical or pesticidal agents that interact with the pathway These Examples are provided merely as illustrative of various aspects of the invention and should not be construed to limit the invention in any way Example 1 : Preparation of Drosophila cDNA Library A Drosophila expressed sequence tag (EST) cDNA library was prepared as follows Tissue from mixed stage embryos (0-20 hour), imaginal disks and adult fly heads were collected and total RNA was prepared Mitochondπal rRNA was removed from the total RNA by hybπdization with biotmylated rRNA specific oligonucleotides and the resulting RNA was selected for polyadenylated mRNA The resulting material was then used to construct a random primed library First strand cDNA synthesis was pnmed using a six nucleotide random primer The first strand cDNA was then tailed with terminal transferase to add approximately 15 dGTP molecules The second strand was primed using a primer which contained a Notl site followed by a 13 nucleotide C-tail to hybridize to the G-tailed first strand cDNA The double stranded cDNA was ligated with BstXl adaptors and digested with Notl The cDNA was then fractionated by size by electrophoresis on an agarose gel and the cDNA greater than 700 bp was purified The cDNA was ligated with Notl, BstXl digested pCDNA-sk+ vector (a derivative of pBluescπpt, Stratagene) and used to transform E coli (XL 1 blue) The final complexity of the library was 6 X 10 6 independent clones The cDNA library was normalized using a modification of the method described by Bonaldo et al (Genome Research (1996) 6 791-806) Biotmylated driver was prepared from the cDNA by PCR amplification of the inserts and allowed to hybridize with single stranded plasmids of the same library The resulting double-stranded forms were removed using strepavidin magnetic beads, the remaining smgle stranded plasmids were converted to double stranded molecules using Sequenase (Amersham, Arlington Hills, IL), and the plasmid DNA stored at -20°C pπor to transformation Ahquots of the normalized plasmid library were used to transform E coli (XL 1 blue or DH10B), plated at moderate density, and the colonies picked into a 384-well master plate containing bacterial growth media using a Qbot robot (Genetix, Christchurch, UK). The clones were allowed to grow for 24 hours at 37° C then the master plates were frozen at -80° C for storage. The total number of colonies picked for sequencing from the normalized library was 240,000. The master plates were used to inoculate media for growth and preparation of DNA for use as template in sequencing reactions. The reactions were primarily carried out with primer that initiated at the 5' end of the cDNA inserts. However, a minor percentage of the clones were also sequenced from the 3' end. Clones were selected for 3' end sequencing based on either further biological interest or the selection of clones that could extend assemblies of contiguous sequences ("contigs") as discussed below. DNA sequencing was carried out using ABI377 automated sequencers and used either ABI FS, dirhodamine or BigDye chemistries (Applied Biosystems, Inc., Foster City, CA). Analysis of sequences were done as follows: the traces generated by the automated sequencers were base-called using the program "Phred" (Gordon, Genome Res. (1998) 8: 195-202), which also assigned quality values to each base. The resulting sequences were trimmed for quality in view of the assigned scores. Vector sequences were also removed. Each sequence was compared to all other fly EST sequences using the BLAST program and a filter to identify regions of near 100% identity. Sequences with potential overlap were then assembled into contigs using the programs "Phrap", "Phred" and "Consed" (Phil Green, University of Washington, Seattle, Washington; http:/ bozeman.mbt.washington.edu/phrap.docs/phrap.html). The resulting assemblies were then compared to existing public databases and homology to known proteins was then used to direct translation of the consensus sequence. Where no BLAST homology was available, the statistically most likely translation based on codon and hexanucleotide preference was used. The Pfam (Bateman et al. , Nucleic Acids Res. (1999) 27:260-262) and Prosite (Hofmann et al, Nucleic Acids Res. (1999) 27(1):215-219) collections of protein domains were used to identify motifs in the resulting translations. The contig sequences were archived in an Oracle-based relational database (FlyTag™, Exelixis, Inc., South San Francisco, CA) Example 2: Discovery of Novel Targets from a P-Lethal Screen dmHelicase was discovered from a screen using collections of P element transposon-induced recessive lethal mutations (P lethals) to identify novel genes. Briefly, genomic sequence suπounding transposable element 1(3)06945, (http ://www. fruitflv. or /cgi - biri/bfd/bfd_namescarch.p ?callcr_class ;;; fonn&t\pcs= : Inscrtion&cluc= ; l%283%2906945&cs=&cc==) was retrieved by inverse PCR, and blasted against the FlyTag™ database, which resulted in identification of pertinent clones for full-length cloning. dmPITP was discovered from a screen using collections of P element transposon induced recessive lethal mutations (P lethals) to identify novel genes Briefly, genomic sequence suπounding transposable element EP(3)0513 (GI3738449 3pnme Drosophila melanogaster EP line Drosophila melanogaster genomic Sequence recovered from 3' end of P element, genomic survey sequence) was retrieved by inverse PCR, and BLASTed agamst the FlyTag™ database, which resulted in identification of pertinent clones for full-length cloning dmSPLl was discovered from a screen using collections of P element transposon induced recessive lethal mutations (P lethals) to identify novel genes Briefly, genomic sequence suπounding transposable element 1(2)05091 (http //www fruitfly org/cgi- bιn/bfd/transposon_report pl^transposon=l (2)05091) was retrieved by inverse PCR, and BLASTed agamst the FlyTag™ database, which resulted m identification of pertinent clones for full-length clonmg Example 3: Cloning of Subject Nucleic Acid Sequences Unless otherwise noted, the PCR conditions used for cloning the nucleic acid sequences set forth in SEQ ID NOS 1, 3, and 5 was as follows A denaturation step of 94° C, 5 mm, followed by 35 cycles of 94° C 1 mm, 55° C 1 mm 72° C 1 mm, then, a final extension at 72° C 10 mm All DNA sequencing reactions were performed using standard protocols for the BigDye sequencing reagents (Applied Biosystems, Inc ) and products were analyzed using ABI 377 DNA sequencers Trace data obtained from the ABI 377 DNA sequencers was analyzed and assembled into contigs using the Phred-Phrap programs Well-separated, single colonies were streaked on a plate and end-sequenced to verify the clones Single colonies were picked and the enclosed plasmid DNA was purified using Qiagen REAL Preps (Qiagen, Inc , Valencia, CA) Samples were then digested with appropriate enzymes to excise insert from vector and determme size, for example the vector pOT2, (www fruitfly org/EST/pOT2 vector html) and can be excised with Xhol/EcoRI, or pBluescπpt (Stratagene) and can be excised with BssH II Clones were then sequenced usmg a combination of primer walking and in vitro transposon tagging strategies For primer walking, primers were designed to the known DNA sequences in the clones, using the Pnmer-3 software (Steve Rozen, Helen J Skaletsky (1998) Pπmer3 Code available at http //www- genome wi mit edu/genome_software/other/pπmer3 html ) These primers were then used in sequencing reactions to extend the sequence until the full sequence of the insert was determined The GPS-1 Genome Pπming System in vitro transposon kit (New England Biolabs, Inc , Beverly, MA) was used for transposon-based sequencing, following manufacturer's protocols Bπefly, multiple DNA templates with ran' lomly interspersed primer-binding sites were generated. These clones were prepared by picking 24 coloiiies/clone into a Qiagen REAL Prep to purify DNA and sequenced by using supplied primers to perform bidirectional sequencing from both ends of transposon insertion. Sequences were then assembled using Phred/Phrap and analyzed using Consed. Ambiguities in the sequence were resolved by resequencing several clones. This effort resulted in identification of various nucleic acid molecules, which are described in detail below. dmHelicase A dmHelicase nucleic acid molecule was identified in a contiguous nucleotide sequence of 1776 bases in length, encompassing an open reading frame (ORF) of 1443 nucleotides encoding a predicted protein of 481 amino acids. The ORF extends from base 162- 1604 of SEQ ID NO: 1. dmPITP A dmPITP nucleic acid molecule was identified in a contiguous nucleotide sequence of 1066 bases in length, encompassing an open reading frame (ORF) of 816 nucleotides encoding a predicted protein of 272 amino acids. The ORF extends from base 183-998 of SEQ ID NO:3. dmSPL A dmSPL nucleic acid molecule was identified in a contiguous nucleotide sequence of 2060 bases in length, encompassing an open reading frame (ORF) of 1635 nucleotides encoding a predicted protein of 545 amino acids. The ORF extends from base 110-1744 of SEQ ID NO:5. Example 4: Analysis of Identified Nucleic Acid Sequences Upon completion of cloning described above, the sequences were analyzed using the Pfam and Prosite programs. dmHelicase Pfam recognized ATPase domain associated with various cellular activities (PF00004) at amino acids 68-411 of SEQ ID NO:2, coπesponding to nucleotides 366-1395 of SEQ ID NO: l. Prosite recognized several putative motifs, which are summarized in Table 1 : TABLE 1 Nucleotide and amino acid sequences for the dmHelicase nucleic acid sequence and its encoded protem were searched agamst all available nucleotide and ammo acid sequences in the public databases, using BLAST (Altschul et al , supra) Table 2 below summaπzes the results The 5 most similar sequences are listed TABLE 2 The closest homolog predicted by BLAST analysis is a RuvB-hke DNA hehcase TIP49b from humans, shanng 78% identity and 90% homology with dmHelicase TIP49a and TIP49b are both mammalian homologs of bacterial RuvB, and are found in the same -700 kDa complex m the cell TIP49a and TIP49b share similar enzymatic properties and have ATPase activity, however, the polanty of TIP49b's hehcase activity (5' to 3', same as RuvB) is reversed relative to TIP49a Both TIP49a and TIP49b have been shown to be independently essential for cell growth, suggesting that their activities are not complementary While dmHelicase is clearly a DNA-hehcase of the RuvB type with strong sequence identity to TIP49b, it is not clear that this is the eukaryotic orthologue of bacterial RuvB There is closer homology amongst the eukaryotic TIP49s and dmHelicase (60-90%), than there is to the bacterial RuvB's (27%) Closer homology to eukaryotic sequences might suggest that either eukaryotic RuvB-type hehcases diverged very early m evolution, and have smce evolved at similar rates Alternatively, it might be that the TIP49s and dmHelicase may form an as yet unidentified sub-family of RuvB-hke hehcases with vanance m specificity BLAST results for the dmHelicase ammo acid sequence indicate 24 ammo acid residues as the shortest stretch of contiguous ammo acids that is novel with respect to pπor art sequences and 49 ammo acids as the shortest stretch of contiguous ammo acids for which there are no sequences contamed withm public database sharing 100% sequence similanty dmPITP Prosite predicted the following putative motifs Protein tyrosine kmase phosphorylation sites at ammo acid residues 63-65, 170-172, 173-175, 217-219, and 233-235 (nucleotides 371-377, 692-698, 701-707, 833-839, and 881-887), Casern kinase II phosphorylation sites at ammo acid residues 13-16, 24-27, 208-211, 240-243, and 251-254 (nucleotides 221-230, 254-263, 806-815, 902-911, 935-944), tyrosine kmase phosphorylation site at ammo acids 160-168 (nucleotides 662-686), and N-mynstolation sites at ammo acids 34-39, and 54-59 (nucleotides 284-299, and 344-359) Nucleotide and ammo acid sequences of the dmPITP nucleic acid sequence and its encoded protein were searched agamst all available nucleotide and ammo acid sequences in the public databases, usmg BLAST (Altschul et al , supra) Table 3 below summaπzes the results The 5 most similar sequences are listed TABLE 3 The dmPITP gene and protem disclosed here is the first PITP described outside of mammalian cells The closest homolog predicted by BLAST analysis is a human phosphatidyl transfer protein, sharing 64% identity and 77% similarity with dmPITP The BLAST analysis also revealed several other PITP proteins which share significant amino acid homology with dmPITP. The dmPITP is difficult to classify on the basis of primary sequence identity alone. The mammalian alpha and beta isoforms are quite distinct, sharing only 77% identity in human, while the alpha isoform is 97-98% identical between human and rabbit, mouse and rat. However, dmPITP is 59% identical with human PITP-α and 64% identical with human PITP-β. The areas of greatest sequence deviation involve charge reversals in the 110-130 region, an insertion between 50-60, loss of a charge at 160 and an excision at 190. Phylogenetically, dmPITP is perhaps more closely related to the beta isoforms, but is nearly equally distal from both sub-families. One means of classifying this protein may be to profile its lipid binding propensities. The capability to bind sphingomyehn in addition to PI and PC would identify this as more similar to PITP-β and exclude it from the PITP-α sub-family. BLAST results for the dmPITP amino acid sequence indicate 14 amino acid residues as the shortest stretch of contiguous amino acids that is novel with respect to prior art sequences and 27 amino acids as the shortest stretch of contiguous amino acids for which there are no sequences contained within public database sharing 100% sequence similarity. dmSPL The predicted domains include: a transmembrane domain at amino acids 300-316 (nucleotides 1009-1057); a pyridoxal dependent decarboxylase conserved domain (PF 00282) at amino acids 192- 306 (nucleotides 685-1027); a cystein/methionin metabolism PLP dependent enzyme domain (PFO1053) at amino acids 133-431 (nucleotides 508-1402); and a DegT, DnrJ, EryCl, StrS family (PF01041) at amino acids 138-522 (nucleotides 523-1675). Nucleotide and amino acid sequences for the dmSPLl nucleic acid sequences and their encoded proteins were searched against all available nucleotide and amino acid sequences in the public databases, using BLAST (Altschul et al, supra). Table 4 below summarizes the results. The 5 most similar sequences are listed. TABLE 4 The closest homolog predicted by BLAST analysis is a sphingosine phosphate lyase from mouse, with 49% identity and 69% similarity with dmSPLl The BLAST analysis also revealed several other protems that share significant ammo acid homology with dmSPLl BLAST results for the dmSPLl ammo acid sequence indicate 15 ammo acid residues as the shortest stretch of contiguous ammo acids that is novel with respect to prior art sequences and 36 ammo acids as the shortest stretch of contiguous amino acids for which there are no sequences contained withm public database sharing 100% sequence similarity Example 5: Assays for ATP hydrolysis ATPase activity is assayed by use of activated charcoal (Sigma, St Louis, MI) as described previously (Armon et al , J Biol Chem (1990) 265 20723-20726) The reaction (20 μl) contams 0 3 μg of the purified dmHelicase, unless specified otherwise The dmHelicase is incubated at 37 °C for 30 mm m A buffer (20 mM Tπs/HCl (pH 7 5), 70 mM KC1, 2 5 mM MgCl 2 , 1 5 mM dithiothreitol, 0 1 mM ATP, and 1 25 mCi of [γ32P]ATP) One microgram of M13 smgle-stranded DNA (ssDNA), double-stranded pBluescnpt DNA (Stratagene, LaJolla, CA), RNA homopolymers (Amersham Pharmacia Biotech), or cellular total RNA is added to each reaction Radioactivity is determined as Cerenkov radiation Control reactions without dmHelicase are earned out in parallel tubes, and the control value (radioactivity) is subtracted from each expenmental one Each assay is done m duplicate, and the results are presented as a simple anthmetic average Example 6: DNA Helicase assay A complementary oligonucleotide coπesponding to nucleotide positions 6291-6320 in M13mpl 8 ssDNA is synthesized and labeled at the 5'-end by T4 polynucleotide kmase and [γ-32P]ATP The labeled oligonucleotide is annealed with the phage ssDNA by incubation at 95 °C for 10 mm and 60 mm at 37 °C The product is purified to remove the unannealed oligonucleotide A complementary oligonucleotide (54-mer) including the Smal site, coπesponding to nucleotide positions 6226-6279 m M 13mp 18 ssDNA, is synthesized and hybridized with the phage ssDN A The oligonucleotide is labeled with T4 DNA kinase for 5 '-end labeling or with terminal deoxynucleotidyl transferase and [γ- 32P]ddATP for 3 '-end labeling After Smal digestion, this partial duplex DNA is used as a substrate For the DNA hehcase assay, the reaction mixture (20 μl) contains 20 mM Tns/HCl (pH 7 5), 2 mM dithiothreitol, 50 mg/ml BSA, 0 5 mM MgCl 2 , 80 mM KC1, 1 mM ATP, and 10 ng of 32P-labeled hehcase substrate The reactions also contain 0 2 μg of the purified dmHelicase Compounds that might modulate the hehcase activity may also be added as competitiors (0 2μg) The hehcase assay is performed at 37 °C for 30 mm and stopped by the addition of 5 ml of 60 mM EDTA, 0 75% SDS, and 0 1% bromphenol blue The reaction mixture is then subjected to 10% PAGE, and the displaced oligonucleotides are visualized by autoradiography Example 7: Purification of dmPITP Clones contammg dmPITP sequence are subcloned into the BamHI-Sall restriction sites of the pBluescnpt vector and transformed into XL 1 -Blue cells (Stratagene, La Jolla, CA) Positive clones are resequenced to verify the coπect clones Inserts are then subcloned into the expression vector pET21 a to generate the dmPITP-hexahistidme fusion construct and transformed into BL21(DE3) cells (Novagen, Madison, WI) DmPITP is induced with isopropyl b-D-thiogalactoside (IPTG, 0 1 mM) for 4 hr at room temperature and bacterial cells are collected by centnfugation The pellet is resuspended in buffer contammg 50 mM sodium phosphate and 300 mM NaCl (pH 8 0) Lysozyme (1 mg/ml) is then added and incubated at 4°C for 30 mm The sample is then sonicated 6 x 1 mm on ice and centπfuged at 10,000 x g for 30 mm at 4°C The supernatant is mixed with Nι 2+ -NTA agarose resm (QiagenNalencia, CA) (4 ml of a 50% ΝTA slurry) for 30 mm at 4°C and then transfeπed to a prepared column The column is washed with 12 bed volumes with buffer contammg 50 mM sodium phosphate, 300 mM NaCl. and 10% glycerol at pH 6 0 (wash buffer), followed by 6 bed volumes of wash buffer but contammg 525 mM NaCl and 6 bed volumes containing 525 mM NaCl and 25 mM lmidazole Protein is then eluted with 1 5 bed volumes of wash buffer contammg 525 mM NaCl and 250 mM lmidazole dmPITP is then exchanged into 20 mM Pipes, 137 mM NaCl, 3 mM KC1 (pH 6 8), and loaded onto Superdex-75 (Pharmacia, Kalamazoo, MI)) Active fractions (assayed by in vitro PI transfer activity ) are pooled and concentrated Example 8: Assays for Phosphatidylinositol (PI) and Phosphatidylcholine (PC) transfer PI transfer activity is assayed as descπbed previously (Thomas et al , supra) This assay measures the transfer of [ 3 H]-PI from rat liver microsomes to unlabeled hposomes in the presence of transfer protein dmPITP) Protein samples of dmPITP are added to tubes containing [ H]PI-labeled microsomes (62 5 μg of microsome protein), hposomes (50 nmol of phosphohpid, 98 mol % PC 2 mol % PI), and SET buffer (0 25 M sucrose, 1 mM EDTA, and 5 mM Tπs-HCl (pH 7 4)) in a final volume of 125 μl Pharmaceutical or insecticidal compounds may be added along with dmPITP at this stage After incubation at 27 °C for 30 minutes, microsomes are precipitated by the addition of 25 μl of ice- cold 0 2 M sodium acetate (pH 5 0) and removed by centnfugation (12,000 X g for 15 mm) A 100-μl aliquot of the supernatant is measured for radioactivity Assay for PC transfer activity measures the transfer of radioactivity from [ 3 H]PC-labeled hposomes to rat liver mitochondria The hposomes consist of 2 mmol of egg yolk PC/ml containing 1 μCi of [ 3 H]PC m SET buffer and are sonicated on ice prior to use [ 3 H]PC-labeled hposomes (40 nmol) are incubated with dmPITP (in presence or absence of compounds) and rat liver mitochondria (2 mg of protem) m a final volume of 0 2 ml of SET buffer for 30 mm at 37 °C The reactions are halted by placing samples on ice, and mitochondria are sedimented by centnfugation at 12,000 X g for 10 mm The sedimented mitochondria are resuspended in 0 5 ml of SET buffer and sedimented by centnfugation at 12,000 X g for 10 mm through 0 5 ml of 14 3% sucrose The pellet is resuspended m 50 μl of 10% SDS and boiled for 5 mm, and this solution is counted for radioactivity Example 9: Sphingosine-phosphate lyase assay Lyase activity is measured by following the formation of labeled fatty aldehyde (and further metabolites) from [ 3 H]dιhydrosphιngosιne-phosphate Assays are performed in glass tubes (13 x 100 mm) as follows An aliquot of [ 3 H]dιhydrosphιngosme - phosphate (10 nmol), dissolved in methanol, is placed in a tube and dπed under N2 To dissolve this material, 25 μL of 1 % (w/v) Triton X-100 is added, followed by 175 μL of reaction mixture In order to ensure complete dissolution of the hpid, tubes are placed m a bath sonicate for 30 sec Reactions are started by addmg 50 μL of sample, in presence or absence of compounds , diluted m a homogenization medium Standard final concentrations are 50 mM sucrose , 100 mM K-p hosphate buffer pH 7 4 , 25 mM NaF , 0 1 % (w/v) Triton X-100 , 0 5 mM EDTA , 2 mM DTT , 0 25 mM pyπdoxal phosphate , 40 μM dihydrosphingosme-phosphate After 1 hr of mcubation at 37 °C, reactions are terminated by adding 0 3 mL of 1 % (w/v) HC10 4 , followed by 2 1 mL of chloroform methanol (1/2 - v/v) After vortexmg, phase separation is induced by addmg 0 7 ml of 1 % (w/v) HCIO4 and 0 7 ml of chlorofom Tubes are again vortexed and centπfuged The upper phase is removed and the lower phase is washed twice with 1 4 mL of 1 % (w/v) HClO methanol (8/2 -v/v) An aliquot of the lower phase (1 mL/1 25 mL total) is transfeπed to another tube, dried under N 2 , and dissolved in 50- 100 μL of chloroform, containing palmitic acid, palmitol and palmitaldehyde, each 5 mM final concentration Ahquots (20 μL) are spotted on silica 60 G plates (Merck, Rahway, NJ) and developed in solvent F (hexane/diethyl ether/acetic acid 70/29/1 v/v) and/or G (chloroform/methanol/acetic acid 50/49/1 v/v) The first system is used if separation of the fatty aldehyde metabolites is required After development, plates are allowed to dry and exposed to iodine fumes Selective staining for aldehyde is also performed Regions of interest are scraped into scintillation vials containing lmL of 1 % (w/v) SDS Before counting, 8 mL of Instagel II (Canbeπa-Packard, Meπden, CT, USA) is added to the vials When separation of the metabolites is not needed, solvent G is employed In this more polar solvent, all metabolites run close together near the front In this case the whole region is scraped into vials and counted

Claims: CLAIMS What is claimed is: 1. An isolated nucleic acid molecule of less than about 15 kb in size comprising a nucleic acid sequence that encodes an invertebrate receptor polypeptide and that shares at least about 75% nucleotide sequence identity with the sequence set forth in SEQ ID NO: 1 , or the complement thereof. 2. An isolated nucleic acid molecule of less than about 15 kb in size comprising a nucleic acid sequence that encodes an invertebrate receptor polypeptide and that shares at least about 75% nucleotide sequence identity with the sequence set forth in SEQ ID NO:3, or the complement thereof. 3. An isolated nucleic acid molecule of less than about 15 kb in size comprising a nucleic acid sequence that encodes an invertebrate receptor polypeptide and that shares at least about 75% nucleotide sequence identity with the sequence set forth in SEQ ID NO:5, or the complement thereof. 4. An isolated nucleic acid molecule comprising a nucleic acid sequence that encodes a polypeptide comprising at least 36 amino acids that share 100% sequence identity with 36 contiguous amino acids of SEQ ID NO:2. 5. The isolated nucleic acid molecule of Claim 4 wherein said nucleic acid sequence encodes the entire sequence of SEQ ID NO:2. 6. The isolated nucleic acid molecule of Claim 4 wherein said nucleic acid sequence encodes a polypeptide having helicase activity. 7. An isolated nucleic acid molecule comprising a nucleic acid sequence that encodes a polypeptide comprising at least 27 amino acids that share 100% sequence identity with 27 contiguous amino acids of SEQ ID NO:4. 8. The isolated nucleic acid molecule of Claim 7 wherein said nucleic acid sequence encodes the entire sequence of SEQ ID NO:4. 9. The isolated nucleic acid molecule of Claim 7 wherein said nucleic acid sequence encodes a protein having phospholipid transfer activity. 10. An isolated nucleic acid molecule comprising a nucleic acid sequence that encodes a polypeptide comprising at least 46 amino acids that share 100% sequence identity with 46 contiguous amino acids of SEQ ID NO:6. 11. The isolated nucleic acid molecule of Claim 10 wherein said nucleic acid sequence encodes the entire sequence of SEQ ID NO:6. 12. The isolated nucleic acid molecule of Claim 10 wherein said nucleic acid sequence encodes a protein having sphingosine phosphate lyase activity. 13. A vector comprising the nucleic acid molecule of any one of Claims 1, 4, 5, or 6. 14. A host cell comprising the vector of Claim 13. 15. A vector comprising the nucleic acid molecule of any one of Claims 2, 7, 8, or 9. 16. A host cell comprising the vector of Claim 15. 17. A vector comprising the nucleic acid molecule of any one of Claims 3, 10, 11, or 12. 18. A host cell comprising the vector of Claim 17. 19. A process for producing an invertebrate helicase protein comprising culturing the host cell of Claim 14 under conditions suitable for expression of said helicase protein and recovering said protein. 20. A process for producing an invertebrate phosphatidylmositol transfer protein (PITP) comprising culturing the host cell of Claim 16 under conditions suitable for expression of said PITP and recovering said protein. 21. A process for producing an invertebrate sphingosine phosphate lyase (SPL) comprising culturing the host cell of Claim 18 under conditions suitable for expression of said SPL and recovering said protein. 22. A purified protein comprising an amino acid sequence having at least about 80% sequence identity with any one of the sequences set forth in SEQ ID NOS:2, 4, or 6. 23. A method for detecting a candidate compound that interacts with a helicase protein or fragment thereof, said method comprising contacting said helicase protein or fragment with one or more candidate molecules, and detecting any interaction between said candidate compound and said helicase protein or fragment; wherein the amino acid sequence of said helicase protein comprises an amino acid sequence which is at least about 80% identical to the sequence set forth in SEQ ID NO:2. 24. A method for detecting a candidate compound that interacts with a phosphatidylmositol transfer protein (PITP) or fragment thereof, said method comprising contacting said PITP or fragment with one or more candidate molecules, and detecting any interaction between said candidate compound and said PITP or fragment; wherein the amino acid sequence of said PITP comprises an amino acid sequence which is at least about 80% identical to the sequence set forth in SEQ ID NO:4. 25. A method for detecting a candidate compound that interacts with a sphingosine phosphate lyase (SPL) or fragment thereof, said method comprising contacting said SPL or fragment with one or more candidate molecules, and detecting any interaction between said candidate compound and said SPL or fragment; wherein the amino acid sequence of said SPL protein comprises an amino acid sequence which is at least about 80% identical to the sequence set forth in SEQ ID NO:6. 26. The method of any one of Claims 23-25, wherein said candidate compound is a putative pesticidal or pharmaceutical agent. 27. The method of any one of Claims 23-25, wherein said contacting comprises administering said candidate compound to cultured host cells that have been genetically engineered to express said protein. 28. The method of any one of Claims 23-25, wherein said contacting comprises administering said candidate compound to a metazoan invertebrate organism that has been genetically engineered to express said protein. 29. A first animal that is an insect or a woπn that has been genetically modified to express or mis- express a protein, or the progeny of said animal that has inherited said protein expression or misexpression, wherein said protein comprises an amino acid sequence that shares at least about 80% identity with a sequence as set forth in any of SEQ ID NOS:2, 4, or 6. 30. A method for studying activity of a protein, comprising detecting the phenotype caused by the expression or mis-expression of said protein in the first animal of Claim 29. 31. The method of Claim 30 additionally comprising observing a second animal having the same genetic modification as said first animal which causes said expression or mis-expression of said protein, and wherein said second animal additionally comprises a mutation in a gene of interest, wherein differences, if any, between the phenotype of the first animal and the phenotype of the second animal identifies the gene of interest as capable of modifying the function of the gene encoding said protein. 32. The method of Claim 30 additionally comprising administering one or more candidate compounds to said animal or its progeny and observing any changes in a biological activity associated with said protein in said animal or its progeny.

Inventors: EBENS ALLEN JAMES JR, KEEGAN KEVIN PATRICK, STOUT THOMAS J, EBENS, ALLEN, JAMES, JR., KEEGAN, KEVIN, PATRICK, STOUT, THOMAS, J.
Applicants: EBENS ALLEN JAMES JR, GENOPTERA LLC, KEEGAN KEVIN PATRICK, STOUT THOMAS J, EBENS, ALLEN, JAMES, JR., GENOPTERA, LLC, KEEGAN, KEVIN, PATRICK, STOUT, THOMAS, J.
Application year: 2000
Main classification: C12N15
IPC codes: C07K14, C12N9, C12N15